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ABSTRACT 
 
There are more than 6,052 identified genetic mutations linked to disease in humans 
and animals. Thanks to the advent of gene editing based on programmable nucleases and 
the advances in DNA sequencing and writing technologies, it is now possible to make 
precise changes in eukaryotic genomes with the potential to correct monogenic diseases, 
from affected cells, tissues, organisms and eventually whole populations. This is the 
concept behind therapeutic genome editing, which arises out of the idea that instead of 
pursuing palliative care, the ideal therapy for monogenic diseases would be to develop a 
method that can directly correct the disease-causing mutations.  
 
Many of these disease alleles have been have been unknowingly co-selected when 
performing phenotypic genetic selection on plants and animals. Although selected 
breeding has been successful in the establishment and improvement of many different 
strains of plants and breeds of animals, we have been propagating these disease alleles in 
the populations. One of these deleterious alleles is the Glycogen Branching Enzyme 
Deficiency (GBED), which is caused by a nonsense mutation (C > A) in the first exon of 
the GBE1 gene that severely disrupts glycogen metabolism. This mutation is lethal in 
homozygotes and an estimated 9% of Quarter Horse and Paint Horse lineages are 
heterozygote carriers. In this work, we corrected this mutation in a heterozygous cell line 
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derived from a high genetic merit American Quarter Horse stallion, by using CRISPR-
Cas9. The long-term goal is to use the corrected cell lines for somatic cell nuclear transfer 
(SCNT) thereby generating a cloned animal that maintains the genetic merit of its 
predecessor, but is free of the GBED mutation.  
 
Precise genome editing requires the introduction of a double stranded break (DSB) at 
an exact location in the genome and the correct DNA repair outcome. Although CRISPR-
Cas9 has allowed for the introduction of precise DSBs in a very efficient manner, the lack 
of control over cell-autonomous repair mechanisms namely non-homologous end-joining 
(NHEJ) and homologous recombination (HR), is still the major bottle neck for seamless 
genome editing. The DNA-dependent protein kinase (DNA-PK), composed of the Ku 70 
- Ku 80 heterodimer and the DNA-PK catalytic subunit (DNA-PKcs), is best known as the 
NHEJ molecular sensor for DNA damage, but has been also identified as a pattern 
recognition receptor (PRR) that defends against the invasion of foreign nucleic acids. Here 
we devised a novel strategy that capitalizes on the natural ability of the Vaccinia virus 
(VACV) C16 protein that evolved as an elegant subversion mechanism to inhibit the 
detection of the VACV genome by the host cytoplasmic PRR defenses, specifically the 
Ku-mediated DNA sensing.  
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
“They thought their classified species were more fixed and unchangeable than anything in 
heaven or earth that we can now imagine. We have learned that they are as plastic in our 
hands as clay in the hands of the potter or color on the artist's canvas, and can readily be 
molded into more beautiful forms and colors than any painter or sculptor can ever hope to 
bring forth”. 
Luther Burbank, 1901 
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1.1 History of Genetic Engineering. 
 
“Appreciation of the history of a discipline helps shape its future.” (1) 
 
 The field of genetic engineering (GE) began in the early 1970s, thanks to the 
development of the recombinant DNA technology (2), which allowed for the 
establishment  of the first recombinant viral vector by Paul Berg in 1971 and the first 
genetically modified organism, a bacteria transformed with a recombinant plasmid 
conferring antibiotic resistance in 1973 by Stanley Cohen and John Morrow et al., (3, 4). 
This group was also the first to report first direct transfer of DNA between different 
kingdoms by expressing Xenopus genes in bacteria(4).  
 
 In 1974, the first genetically modified animal was produced by Rudolf Jaenisch 
and Beatrice Mintz (5) by microinjecting the whole DNA of the Sivian Virus - 40 (SV-
40) into an expanded blastocyst and showing the presence of the transgene in the cells of 
healthy adult mice. Followed by Gordon in 1980 (6), were a recombinant plasmid 
containing DNA fragments of the SV-40 virus was microinjected into the pronuclei of 
fertilized mouse embryos, with later demonstration of the transgene transmission to 
subsequent generations in 1981 (7-9).  
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  But the process of how the DNA was finding its way into the genome was still not 
understood until July of 1982, when Mario Capecchi published the intriguing observation 
that when many copies of a gene were inserted into the genome, the pattern of integration 
was the opposite of the expected random integration. He found that the genes were always 
clustered in one or a few regions, with many copies overlapping one another. Cappecchi 
had discovered that mammalian cells could undergo homologous recombination. At the 
end of his 1982 article he stated, “It will be interesting to determine whether we can exploit 
this machinery to "target" a gene by homologous recombination to a specific chromosomal 
location” (10). Just three years later, Oliver Smithies published a paper where they 
exploited this possibility to precisely target the human ß-globin locus and introduce a 
neomycin resistance gene in a predictable fashion, albeit with the planned modification 
occurring in one per thousand transformed cells (0.001%) (11). These were milestone 
papers that began the exponential growth in the field of genetic engineering. 
 
By December of 1982, Richard Palmiter and Ralph Brinster published the 
establishment of the famous growth enhanced “gigantic mice” (12). Then in 1985, Robert 
Hammer created the first genetically modified farm animals (13). With these innovations, 
the field of genetically engineered animals opened its doors to the agricultural production, 
providing the tools for the introduction of new traits that could not be produced by 
selective breeding, or traits that would take several decades of breeding to achieve. 
4 
Pronuclear microinjection (PNMI) gave rise to the initial development of the field 
and allowed the production of many different GE animals including rodents, rabbits, pigs, 
sheep, goats, cattle, salmon and other fishes (13-16). However, the technology was still 
very inefficient (≤1% of injected zygotes will produce a viable transgenic animal) and did 
not allow for any control in the copy number, stable expression, or the integration site of 
the transgene (16). This was important because if the integration occurred within a 
heterochromatic region, the transgene was most often silenced. Further, it was later 
revealed that the regulatory elements of nearby genes affected the level of expression, or 
conversely, the transgene could interfere with the transcriptional control of critical genes 
impacting growth and development (16, 17). This pushed the field of genetic engineering 
to improve integration and expression efficiency, and it rapidly increased our 
understanding of the functional importance of regulatory elements such as promoters, 
enhancers and insulator sequences for reduced gene silencing and increased transcription 
of a transgene.  
By 1983 Jack Szostack, Terry Weaver and Rodney Rothstein at Harvard Medical 
School, published a pioneering model based on experimental data on meiotic 
recombination in yeast that explained the mechanism behind homologous recombination 
and gene targeting. They proposed that the event that precipitated homologous 
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recombination was a double stand break (DSB) in the DNA, in which the free ends of the 
DNA at the site of the break were prone to fusing, making the flanking sequences far 
likelier to engage in the exchange of genetic information with the homologous 
chromosome, or in the case of gene editing, with the repair template provided by the 
scientist (18).  
 
 By the end of the 1980s seminal work in Martin Evans laboratory at the University 
of Cambridge, demonstrated that by targeting genes in mouse embryonic stem cells 
(ESCs) with retroviral vectors and then injecting those modified stem cells into mouse 
embryos, chimeric mice with the designed edits in the germ line could be obtained and 
could subsequently be used them for the derivation of transgenic strains (19). This 
milestone, conferred the possibility for having much more control in the type and 
complexity of the genetic modification. The breakthroughs by Capecchi, Smithies and 
Evans earned them the 2007 Nobel prize "for their discoveries of principles for introducing 
specific gene modifications in mice by the use of embryonic stem cells” (20). 
 
Although this ESCs technology has been a huge success in the establishment of 
GE mice and rats, the culture conditions tested so far are not supportive of livestock ESCs 
self-renewal and proliferation making this technology unavailable for the making of GE 
livestock (21). In contrast, numerous reports of derivation of livestock induced pluripotent 
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stem cells (iPSCs) have been made with limited success (22-26). iPSCs were first derived 
in 2006 using mouse fibroblasts by overexpression of four key transcription factors: Oct4, 
Sox2, Klf4, and c-Myc (OSKM) by the Shinya Yamanaka group in Japan (27). The 
livestock iPSCs have demonstrated capacity for long term proliferation and in vivo 
pluripotency, as indicated by teratoma formation assay (22). However, to what extent 
these iPSCs represent fully reprogrammed PSCs remains controversial as most livestock 
iPSCs depend on continuous expression of reprogramming factors and robust germline 
chimerism has not been demonstrated. Although transgenic bovine chimeric offspring 
from embryonic in bovine embryonic stem-like cells (bESC) (28, 29) have been produced 
no germline transmission was demonstrated (29). In summary, alternative technologies 
were necessary to produce transgenic livestock since stem cells were not an option. 
 
 In 1994, Maria Jasin’s laboratory at Memorial Sloan Kettering center in New York 
published a ground-breaking paper (30) that would lay the foundation of genome 
engineering using engineered nucleases. Her lab generated for the first time a specific 
artificial DSB in the mouse genome by using a rare-cutting endonuclease (I-SceI) and 
showed that gene targeted clones were nearly undetectable without the nuclease 
expression, while in contrast, the presence of the nuclease inducing artificial DSBs 
displayed an approximately 10% increase in homologous recombination. The 
implementation of this discovery was not quick because the recognition specificity of 
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meganucleases proved too difficult to tailor to desired target sites. Thus, generation of a 
targeted DSB remained the rate-limiting step in the development of HDR technology for 
genome engineering of plant and mammalian cells, including human cells (31).  
 
 In 1996 at the Roslin Institute, Keith Campbell and Ian Wilmut adapted the nuclear 
transfer technique for the use of mammalian somatic cells (SCNT) (Wilmut et al., 1997), 
based on the previous work that Jon Gurdon had done in 1962 using Xenopus laevis at 
Oxford (32-34). This milestone was established by the birth of “Dolly”, the first mammal 
ever cloned from adult somatic cells. SCNT made possible the controlled insertion of 
precise genetic modifications in livestock by facilitating the verification of genetically 
engineered cell lines prior to SCNT. Using this technology 100% of born animals were 
transgenic. However, due to epigenetic reprograming and developmental issues, the 
abortion rates of cloned fetuses were high, approximately 17%, and there is also a high 
perinatal mortality, making the overall efficiency very low (<5%) and with a high cost of 
implementation(17, 35, 36). 
 
 The first proof of concept, showing the potential of this technology was provided 
by a collaboration between the Roslin Institute and PPL - Therapeutics, upon the birth of 
two transgenic sheep, ‘Polly’ and ‘Molly’, the first genetically engineered (GE) animals 
produced by using SCNT. Here, fetal fibroblasts that were modified to carry the human 
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blood factor IX under the control of the sheep milk ß-lactoglobulin (BLG) promoter and 
a neomycin resistance gene, were used as donor nucleus to generate these sheep (37). 
 
 By 1996, the laboratory of Srinivasan Chandrasegaran in Johns Hopkins 
University developed a novel site-specific hybrid restriction enzyme that fused two 
different zinc finger (FZ) proteins to the non-specific type IIs enzyme FolkI cleavage 
domain, a breakthrough that set the stage for genome engineering using programmable 
nucleases (38). After a few years of technology refinement, the Chandrasegaran lab started 
a collaboration with Dana Caroll that resulted in the use of the designed zinc finger 
nucleases (ZFN) to stimulate homologous recombination in frog oocytes and to edit the 
yellow gene in Drosophila. This was a profound development that showed the promise this 
technology had for precise genome editing in living organisms (39-41).  
 
In spite of their promise, ZFNs were never widely adopted. Each ZF usually 
recognizes 3-bp sequence and binds DNA by inserting the α-helix into the major groove 
of the double helix; however, when there is an aspartic acid residue present at +2 position 
of the α-helix, it can enforce an adenine or a cytosine base outside the 3-bp site at the next 
base on the non-contact strand of DNA via a cross-strand contact, changing the ZFs 
recognition to a 4-bp site. This ZF contact outside the 3-bp site further influences the 
specificity of neighboring ZFs. Once it became ap
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ZFs was not truly modular, where each ZF recognizes a triplet sequence as one had 
expected and that each ZF's recognition was greatly influenced by its neighbors, this 
complicated the design. This meant the selection of each ZF had to be performed in a 
context-dependent fashion to obtain highly sequence specific ZFPs, which is laborious, 
time consuming and requires extensive experience in protein engineering (31). The ZFNs 
had proven that designer nucleases were the right tool to pursue, but the field still needed 
a new kind of technology that would be more reliable and straightforward to use.  
 
This technology arrived in 2009 due to an accidental discovery made in 
Xanthomonas bacteria: a novel DNA-binding protein known as transcription activator-
like effectors (TALE) (42). The TALE central repeat domain consists of repeating units 
of 33–35 amino acids, where each repeat is largely identical except for two highly variable 
amino acids at positions 12 and 13, referred to as the repeat variable di-residues (RVDs). 
While each ZF recognizes 3–4 bases, each TALE motif recognizes a single nucleotide, 
and the recognition specificity is determined by the RVD. More importantly, unlike the 
ZFs, the recognition of DNA by individual TALE modules appears to be largely 
independent of neighboring modules. The DNA recognition code thus provides a one-to-
one correspondence between the array of amino acid repeats and the nucleotide sequence 
of the DNA target, which made them ideal for constructing custom nucleases (43).  
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TALENs development built largely upon the experience gained from ZFN 
development, which made the implementation of this technology much faster than ZFNs. 
But even though TALENs are easier to generate than ZFNs, the genes encoding TALENs 
are about three times larger than ZFNs and the TALE consensus sequences are invariant 
and highly repetitive in nature. This makes it more difficult to assemble the genes encoding 
for TALENs in E. coli and its delivery into mammalian cells is also problematic; finally, 
the initial commercial pricing for TALENs of ~$5000 per target, restricted it use. But only 
3 years after the elucidation of the TALE recognition code, the CRISPR-Cas platform 
arrived on the scene.  
 
1.2. CRISPR-Cas9 
This technology had unpretentious origins. It was first reported in 1987 by Atsuo 
Nakayta in Japan, as an incidental finding of unknown biological significance, where odd 
repetitive sequences were found separated by unique spacer sequences of similar length 
and were clustered next to the iap gene of Escherichia coli K12 (44). By the 1990s, these 
regions were named interspaced direct repeats (DR), and the DR-intervening sequences, 
known as spacers, were found to differ among isolates and were harnessed for strain typing 
in the Mycobacterium tuberculosis complex (MTBC) (45, 46). By the late 1990s, thanks 
to the improvement of sequencing technologies, similar elements were found in archaea 
and bacteria. Bioinformatics analysis on the then called short regularly spaced repeats 
(SRSR) in a large number of unrelated microorganisms suggested a biological relevant 
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function (47). By 2002, the groups of Ruud Jansen in the Netherlands credited the proposal 
of Fransisco Mojica in Spain to unify the diversity of names and labels for these DNA 
repeated elements as CRISPR (clustered regularly interspaced short palindromic repeats), 
and at the same time a set of four genes in vicinity to the clustered repeats was detected 
and named CRISPR-associated (Cas) genes (cas1-cas4) (48).  
 
In 2005, those three bioinformatics groups (49-51) reported that the spacer 
sequences matched the sequences of phages, suggesting a possible role for CRISPR in 
bacterial immunity. This was an important clue that allowed for a hypothesis to be 
formulated: CRISPR was somehow a bacterial immune system involved in the targeted 
recognition by CRISPR-RNA molecules (52), reminiscent of the eukaryotic interference 
RNA that defended the bacteria against viruses (50). One of these studies (51) was also 
the first to observe a short conserved DNA motif next to the protospacers, which would 
later be termed the protospacer adjacent motif (PAM) (53).  
 
  Two years later in 2007, this hypothesis was confirmed experimentally when the 
group of Rodolphe Barrangou and Philippe Hovarth at Danisco, in their landmark 
publication showed that they could alter the resistance of S. Thermophilus to 
bacteriophage infection of a susceptible strain by adding spacer DNA that matched the 
phage’s genome (54). In 2008 Brouns et al., (55) demostrated that the small RNAs 
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produced by the CRISPR arrays (crRNAs) had a crucial role driving antiviral defense and 
that the DNA was the target of CRISPR action. This was subsequently confirmed by 
Marraffini et al., (56) by showing that CRISPR could interfere with the horizontal transfer 
of plasmid sequences through DNA targeting. Together these findings established 
CRISPR-Cas as an efficient adaptive immune system in prokaryotes.  
 
Over the following years a detail characterization of the biochemical mechanism 
of action was progressively made. PAM sequences seemed important for the interference 
(57) and the motifs emerged as common features in many systems (53) until it was defined 
that the CAS protein cleavage occured next to the PAM (58). By 2011 the trans-activating 
crRNA (tracrRNA) was discovered and its crucial role for the generation of mature crRNA 
molecules was shown (59). That same year, the first classification of the CRISPR-Cas 
systems was made into three different functional and structural types (Type I, II and III) 
and subtypes (60). This was later changed to two Classes I (Type I, III and IV) and II 
(Type II and V) with 16 subtypes (61, 62). 
 
 By 2012, two independent teams published the biochemical characterization of in 
vitro characterized CRISPR-Cas systems (63, 64), and for the first time, both groups 
proposed that CRISPR-Cas could be used as a genetic engineering tool. The group of 
Jennifer Doudna in UC Berkeley and Emmanuelle Charpentier in Umeå University of 
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Sweden, showed that the Streptococcus pyogenes tracrRNA, crRNA and Cas9 could be 
used to create a precise DSB in a DNA sequence that matched the crRNA spacer. They 
simplified the system by making a chimeric synthetic RNA molecule between the 
tracrRNA and the crRNA, named single guide RNAs (sgRNA) which also directed 
sequence specific DNA cleavage (Figure 1 A, B), In parallel Sinsnys, Barrarangou and 
Hovart working with the Streptococcus thermophilus CRISPR system demonstrated 
similar results. Together, these two publications resulted in three independent US teams 
assessing in less than 6 months, the genome editing capabilities of the CRISPR system in 
bacteria by Luciano Marraffini group at Rockefeller University (65) and in mammalian 
genomes by the groups of George Church at Harvard Medical School (66) and Feng Zhang 
at MIT (67). These landmark papers triggered a wave of excitement throughout the 
Scientific community and CRISPR-Cas was widely adopted.  
 
 CRISPR-Cas technology is under a constant evolution and refinement; for 
example, researchers inspired by ZFNs and TALENs, have developed Cas9 variants from 
the Streptococcus pyogenes Cas9 (SpyCas9) for use as nickases, dual nickases or FokI 
fusion variants (68-72). Deactivated variants of Cas9 (dCas9) lacking DNA cleavage 
function allow for the fusion of many different domains. For example, sequence-specific 
transcriptional regulation can be made by fusing a transcriptional repressor (e.g., KRAB) 
or activator domain (e.g., VP64) to reduce or increase gene expression, respectively (73-
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75). Epigenetic modifications have also been possible by the fusion of acetyltransferases 
and demethylases (76-78). Fusion of dCas9 to fluorophores, has enabled sequence-specific 
visualization of DNA, and dynamic imaging of chromatin and allowing up to 6 different 
loci using CRISPRainbow (79, 80). Crystallographic and electron-microscopy based 
structures of Cas9 have revealed the nature of its interactions with guide RNA and target 
DNA, which have been exploited for the engineering of Cas9 variants with altered PAM 
specificities (81) and lower off target effects (82). Transcriptional and functional control 
of Cas9-mediated genome editing has been made with optogenetics (83) and chemically 
inducible (doxycycline-regulated) approaches (84). Other Cas9 orthologues, such as the 
smaller Staphylococcus aureus Cas9 that allows for adeno-associated virus (AAV) 
packaging (85), and other nucleases derived from class II CRISPR–Cas systems including 
Cpf1 (86)and C2c1(87), have also been added to the CRISPR repertoire by bioinformatics 
mining of the abundant bacterial and archaeal CRISPR–Cas systems.  
 
1.3. Applications of Gene Editing Technologies  
Gene editing technologies have been used in many different fields such as 
research, therapeutic manufacturing, xenotransplantation, livestock and crop production, 
food and industrial microbes. This section aims to highlight the most important 
applications in each of the aforementioned fields.  
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1.3.1 Animal Disease Models for Research 
 The ability to generate targeted mutations in the mammalian genome has formed 
the backbone of genetic research since the establishment of the first knockout mouse by 
Capecchi, et al (88, 89). Since then, the mouse as a model organism has been at the 
forefront of genetic engineering and has led to many of the discoveries for the currently 
available drugs and treatments (90). However, a high proportion of clinical trials and 
consequently drug development efforts have been met with some unexpected failures. This 
is attributable in part to the mouse data not being translatable to human medicine, and in 
some cases a failure to replicate the symptoms associated with human mutations (91). This 
has pushed the development of new animal models, like the rat (92), rabbit, dog, pig (91), 
sheep (93) , goat, cow and primates that better phenocopy human diseases. For example,  
porcine models of Parkinson’s disease and Von Willebrand disease have been made by a 
triple knockout of DJ-1, parkin, and PINK1 genes (94) and a knock out of the vWF gene 
(95) respectively.  
  
1.3.2 Agricultural Applications  
Genetically engineered (GE) animals have been developed for several purposes, 
that target almost all aspects of animal agricultural production. Farm animals and fish have 
been genetically modified with the aim to enhance economically important traits (96). For 
example, increased growth rate has been attained in pigs (13, 97-100), Atlantic salmon 
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(101) and tilapia (102, 103) by modifying growth hormone expression. Cattle (104) and 
goats (105) lacking the prion protein have been made by knocking out the PrPC protein. 
Mastitis resistant cattle were produced by expressing in the mammary gland either the 
human lysozyme, lactoferrin or lysostaphin (106-109). An increase in meat quality was 
also accomplished in pigs with higher level of polyunsaturated fatty acids (PUFAs) in their 
meat (110, 111). Animals that are resistant to diseases have also been made, for example 
chickens that are resistant to the transmission of the influenza virus (112) and PRSSV 
resistant pigs (113, 114).  Although not applicable yet to animals, there are efforts to make 
an organism resistant to all viruses by repurposing the genetic codons (115).  
 
1.3.3 Biological Control Applications 
Insects act as vectors of disease of plants and humans. The replacement of wild 
insect populations with genetically modified individuals unable to transmit disease, or 
carrying a lethal gene drive to kill the offspring, provides a friendly and self-perpetuating 
method for disease prevention (116). This can be done with gene drives, which are genetic 
systems that circumvent the traditional rules of Mendelian inheritance in sexually 
reproducing organisms (50:50), by greatly increasing the odds that the drive will be passed 
on to offspring, until an entire population bears that gene. These “selfish” genetic elements 
occur naturally in mice, beetles and many other organisms, and named homing 
endonuclease genes (HEGs) (117). The discovery of CRISPR-Cas9 brought gene drive 
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systems (GDS) from a remote possibility back to reality, via the making of efficient self-
perpetuating gene drives that can be deployed in potentially any genomic location in any 
eukaryotic species (118). For example, the malaria transmitting mosquito Anopheles 
gambiae has been targeted with CRISPR-Cas gene drive systems (116). 
 
1.3.4 Organ Transplant 
 The highly disproportional shortage of transplantable organs and the increasing 
number of patients added to the waiting lists, is causing that on average more than 20 
persons die each day due to the lack of a transplant.  This has pushed the search for new 
alternatives such as organ bioreactors and the use of pigs as organ donors for the xenogenic 
transplantation into humans, a process known as xenotransplantation.  One approach is by 
eliminating the molecular immune incompatibility between the donor and the recipient, 
by genetically engineering the pig (119, 120). The other approach is to engineer the pig to 
grown human organs by doing embryo chimeric complementation with pluripotent stem 
cells (121).  
 
1.3.5 Industrial Biotechnology and Therapeutic Manufacturing 
The deficit in the bio-manufacturing capacity of therapeutic proteins and the 
increasing perceived viral risks associated with plasma derived products have led to the 
development of the production of recombinant therapeutic proteins by the use of genetic 
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engineering (122). This technology platform represents a powerful tool to address the 
growing needs of the biopharmaceutical market for a safer, more efficient and less costly 
product. It also enables the production of any type of protein with a physiologically 
relevant function. These proteins can be produced in various hosts, with multiple 
possibilities to design the protein product and also the production process. Currently 
recombinant proteins are the main end product of the biotechnology industrial pipeline 
and include protein hormones, monoclonal antibodies, protein based (sub-unit) vaccines 
and even spider silk (123-132). Different host have been used such as bacteria, yeast, 
insect, mammalian cells and transgenic animals for the production of recombinant proteins 
(127, 133-135). When choosing a system that is most suitable for any given protein target 
many different factors come into play such as post-translational modifications (PTM), 
cost, scale up easiness, total annual production, and speed of production (136). 
 
1.4. Repair of DNA Double-Strand Breaks. 
 Gene editing technologies, including CRISPR-Cas9, rely on the precise 
introduction of a DNA double-strand break (DSB) at a precise location in the genome. 
DSBs are the most dangerous type of DNA damage, which if left unrepaired, can result in 
chromosomal translocations, the loss of large chromosomal regions or can activate cell 
cycle check-point arrests and induce signals for programmed cell death. In dividing 
mammalian cells, there are an estimated ten DNA double-strand breaks (DSBs) per day 
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per cell (137). These pathological DSBs arise from DNA replication errors, reactive 
oxygen species, and genotoxic agents such as ionizing radiation, radiomimetic chemicals 
or topoisomerase inhibitors (138). There are also physiological DSBs that arise during 
normal cellular processes, such as meiosis during gametogenesis or V(D)J recombination 
and class-switch recombination (CSR) which facilitate the rearrangements of antigen 
receptor genes in lymphogenesis (137, 138) (Supplementary Figure 14). 
 
DSBs that occur throughout the cell cycle are repaired predominantly by the non-
homologous DNA end joining (NHEJ) pathway that is present during the G1, S and G2 
phases and to a lesser extent by the homology-directed repair (HDR) pathway that is 
restricted during the late S and G2 phases(139). The classical NHEJ (C-NHEJ) can be 
divided into five main stages: (I) The rapid binding of the Ku70-Ku80 heterodimer to free 
ends of DNA, which induces the recruitment and activation of the DNA-dependent protein 
kinase catalytic subunit (DNA-PKcs). The KU-heterodimer and the DNA-PKcs together 
form the DNA-PK complex. (II) The synaptic end bridging, that is dependent on the 
configuration of the DNA ends (which can include blunt ends, 5ʹ overhangs and 3ʹ 
overhangs), is carried out by the DNA-PK, where the broken DNA ends are kept in close 
proximity. (III) The DNA end processing is carried out because most DSBs have two 
incompatible DNA ends that preclude direct ligation, has many subpathways were end-
processing factors (e.g. PNKP, TDP1), NHEJ polymerase (e.g Pol µ, Pol λ) and nuclease 
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(e.g Artemis) complexes, assure microhomolgy and prepares the DNA ends for (IV) 
ligation of the break by the XRCC4 -XLF-LIG4 complex (139-141) and finally (V) the 
Ku heterodimer removal from the restored DNA (Figure 1).  
 
Structural and biochemical studies support a model in which the degree of 
microhomology (≤4 nucleotides) between the ends, direct repair subpathways; that is, 
which of the different sets of NHEJ proteins serve to align the two DNA ends in an end-
to-end configuration (137). In order to create new microhomology ends, multiple rounds 
of resection and addition are possible, and nuclease and polymerase activities at each of 
the two DNA ends can act independently. The process is very error-prone and can result 
in diverse DNA sequences at the repair junction (139-141). 
 
When NHEJ is compromised owing to the lack of one or more of its key protein 
components, the activity of the other end joining pathways becomes apparent. This 
typically involves amuch more extensive resection of the DNA ends to reveal sequence 
homology; the annealing of which stabilizes the two ends of a break to allow for more 
efficient joining and ligation (137, 142). This 5ʹ to 3ʹ endo- and exo-nucleolytic processing 
is performed by the carboxy-terminal binding protein interacting protein (CtIP) and the 
MRN (MRE11–RAD50–NBS1 (Nijmegen breakage syndrome protein 1)) complex, to 
generate stretches of single-strand DNA (ssDNA) 3’ overhangs. This is a very rapid (~30 
minutes) (143) and highly regulated process by the cell cycle cyclin-dependent kinases 
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(CDKs) (137) by weakening the activity of two distinct blocks to resection: one mediated 
by the chromatin-binding protein 53BP1 (p53- binding protein 1), and a second embodied 
by HELB, an ssDNA translocase(144). These 3’ overhangs are suitable substrate for two 
possible mechanisms: alternative end joining (A-EJ, also known as micro homology-
mediated end joining (MMEJ) or Pol θ-mediated end joining), which uses small sequence 
homologies (~2-20 nt) and is 50-fold less frequent than NHEJ(145); and homologous 
recombination (HR), which relies on extensive homology (~20 - >100 nt). Neither of these 
pathways is reliant on Ku, and the binding of Ku to DNA ends may need to be attenuated 
for a-EJ and HR to proceed (137). 
 
 The HR pathway comprises of at least three sub-pathways: homology directed 
repair (HDR), single stranded annealing (SSA), and the recently recognized single 
stranded template repair (SSTR) (117, 146). Non-conservative homology-directed repair 
pathways (which involve the loss of nucleotides), such as SSA, requires >20 bp of 
homology (137, 147). The conservative HDR pathway, in which no nucleotides are lost, 
generally requires lengths of homology longer than 100 bp (148, 149). HR is a slow 
(~≥7h), but typically an error free process that uses the sister chromatid for repair during 
the late S and G2 phases of the cell cycle) (143). Mechanistically, replication protein A 
(RPA) binds to the ssDNA 3’ ends and subsequently BRCA2 recruits the RAD51, which 
displaces RPA to form a RAD51–ssDNA nucleofilament recombinase, which is required 
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for homology search, strand invasion and ultimately the repair of the lesion (148). For 
heterochromatic regions that can engage in ectopic recombination during DSB repair, 
leading to chromosome rearrangements and widespread genome instability, the HDR 
repair relies on the relocalization of the DSBs to the nuclear periphery before Rad51 
recruitment (150, 151).  
 
The post replicative chromatin marking model is the simplest model for explaining 
HR activation during S phase and proposes that replicated chromatin is competent for HR 
whereas unreplicated chromatin remains refractory to this type of repair (144). The lack 
of methylation at the Lys20 residue of histone H4 (H4K20me0) represents a post-
replicative chromatin mark as well as the presence of cohesin. H4K20me0 is recognized 
by MMS22L–TONSL, which promotes HR by promoting RAD51 loading in response to 
DNA replication stress (141, 144). In contrast, the presence of monomethylated and 
especially dimethylated, H4K20, marks of chromatin damage by DSBs that are induced 
by ataxia-telangiectasia mutated (ATM) monomers, are recognized by 53BP1 which 
rapidly accumulates on the chromatin surrounding the break site and promotes NHEJ and 
opposes HR (and A-EJ) at least in part by blocking DNA end resection (141). Single strand 
annealing, in contrast, mediates annealing between stretches of chromosome-internal 
homologies resulting in the loss of the intervening region, and is therefore considered an 
error prone repair pathway (117, 137, 147, 152, 153). Single stranded template repair has 
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not been fully characterized to date, but is known that requires multiple components of the 
Fanconi Anemia (FA) pathway, but is independent of BRCA2 or Rad51(146, 154) (Figure 
1 C-G). 
 
The high abundance of the Ku molecules in cells (KU70 1,290,000 and KU80 
826,000 molecules per cell) (137) increases the likelihood that the Ku-heterodimer is the 
first protein to bind to a broken DNA end and, therefore, that repair is carried out through 
NHEJ. Although binding of DNA ends by Ku-heterodimer inhibits extensive resection by 
MRN (MRE11–RAD50–NBS1) complex and CtIP (C-terminal binding protein 
interacting protein) (155) favors repair by NHEJ, extensive resection is also dependent on 
the cell cycle owing to the action of cyclin-dependent kinases (CDKs). Factors that 
promote extensive end resection are more active during S and G2 phases and favor HR 
when a sister chromatid is present. This is another reason why repair by NHEJ is dominant 
throughout the cell cycle, whereas repair by HR and SSA is favored in S and G2 phases 
(156-158). Therefore, in G1 phase, NHEJ is favored by more than 50-fold for the repair 
of DSBs, owing to both the level of Ku and the suppression of extensive end resection by 
CtIP and MRN. Even in S and G2 phases, when extensive end resection can take place, 
the resection machinery must still overcome the presence of Ku at DNA ends either by 
outcompeting Ku for DNA-end binding or by processing the DNA ends to the point at 
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which Ku binding is less favored. The ratio of NHEJ to HR in wild-type mammalian 
somatic cells, even during S phase and G2 phase, is estimated to be 4:1 (137, 159) 
 
If Ku is absent (which is exceedingly rare in normal human tissues, as well as in 
neoplastic human tissues), a-EJ may be favored over SSA and HDR in G1 phase, owing 
to the limited amount of resection that a-EJ involves (137). It is still unknown what dictates 
the use of a-EJ versus SSA in S and G2 phases. However, time is likely to be a key 
determinant because the longer a DSB remains unrepaired, the more end processing can 
occur to generate longer 3ʹ ssDNA tails to favor SSA. Studies have shown that NHEJ can 
occur in approximately 30 minutes while HDR lakes 7h or longer, these efficiencies are 
strongly influenced by chromosomal location (143). Lastly, quantification of the relative 
ratio of various pathways is complicated because the absence of one pathway results in 
the accumulation of substrate for other pathway (137)  
 
Finally, although unrelated with repair of DSBs, random integration (RI) of 
exogenous DNA hampers the precise engineering of genomes through recombination of 
exogenous DNA at unanticipated loci. RI does not rely on sequence homology, is more 
efficient than HDR, happens with no or little detectable sequence preference, results in 
insertional mutations, and is hence often referred to as “illegitimate recombination” (160). 
Although the mechanism of RI was unknown, recent publications describe that the dual 
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loss of Pol θ and C-NHEJ LIG4 eliminates off-target integration of exogenous DNA and 
demonstrates the role of A-EJ and C-NHEJ in RI. Here the term TMEJ (polymerase Theta- 
Mediated EJ) is proposed due to the notion that A-EJ may also encompass Pol θ-
independent repair (160, 161). 
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Figure 1. CRISPR-Cas9 Introduction of DSB and DNA Repair Outcomes. 
DNA double-strand breaks (DSBs) can arise in pathological (e.g ionizing radiation) and physiological 
conditions (e.g Meiosis), or by the genome editing technologies, like CRISPR-Cas. A-C) The Streptococcus 
pyogenes CRISPR-Cas9 system. Here Cas9 endonuclease (shown in blue) consists of a nuclease (NUC) lobe 
and a recognition (REC) lobe. Cas9 is targeted to specific DNA sequences by direct pairing of the chimeric 
single guide RNA (sgRNA), an engineered fusion between a crRNA (orange) and part of the tracrRNA 
sequence (purple), with the target DNA by forming a DNA-RNA heteroduplex. This targeting relies on the 
presence of a 5′protospacer-adjacent motif (PAM) in the DNA (green), which in S. pyogenes is usually 
NGG. After PAM recognition, Cas9 unwinds the DNA at the PAM-proximal region and creates a seed RNA-
DNA heteroduplex pairing, next, the R-loop propagates via sequential unwinding to the PAM-distal regions 
(162). Only when extensive pairing has occurred (on-target), Cas9 suffers a conformational change in its 
HNH catalytic domain that triggers the RuvC domain catalytic activity ensuring a coordinated introduction 
of a DSB (163). While the HNH domain cleaves the gRNA complementary strand 3nt 5’ of the PAM, the 
RuvC domain cleaves of the non-complementary strand in a variable location due to the ability for this 
strand to breathe in and out of the nuclease domain (164). The two domains can be mutated (i.e RuvC1 
(D10A) and HNH (H841A)) to create a nuclease null dCas9. B) After the DSB Cas9-DNA complex remains 
bound to the cleaved products for ~6h partially releasing the PAM-distal non-target strand before complete 
dissociation (163, 165). C) If only partial pairing occurs there is no DNA cleavage and Cas9 remains 
unbound to the DNA. The DSB can be repaired by the D) classical non-homologous end joining (NHEJ) 
pathway, E) the alternative end joining (a-EJ) pathway, F) the single-strand annealing (SSA) pathway, G) 
single strand template reapair (SSTR) or H) by homologous recombination (HR). The major differences in 
pathway choice are the requirement for substantial DNA end resection. D) The high abundance of the Ku 
molecules in cells increases the likelihood that Ku-heterodimer is the first protein to bind to a broken DNA 
end and, therefore, that repair is carried out through NHEJ. p53-binding protein 1 (53BP1) is a chromatin 
remodeler and a positive regulator of NHEJ (137). Although the complex of Artemis and DNA-dependent 
protein kinase catalytic subunit (DNA-PKcs) can carry out some resection (typically <20 nucleotides), the 
NHEJ pathway does not require extensive end resection and the ends are mostly protected by the binding of 
Ku70–Ku80. The classical NHEJ (C-NHEJ) can be divided into five main stages: I) The rapid binding of 
the Ku70-Ku80 heterodimer to free ends of DNA, II) the synaptic end bridging, III) the DNA end 
processing, IV) ligation of the break by the XRCC4 -XLF-LIG4 complex (139-141) and finally V) the Ku 
heterodimer removal from the restored DNA. On the other side, the carboxy-terminal binding protein 
interacting protein (CtIP) and the MRN (MRE11–RAD50–NBS1 (Nijmegen breakage syndrome protein 1)) 
complex are involved in extensive 5ʹ to 3ʹ resection of regions of the duplex to generate stretches of single-
strand DNA (ssDNA) at DNA ends for A-EJ, SSA and HR. D) SSA typically requires >20 bp of 
microhomology, whereas the requirement for E) a-EJ is <25 bp. Poly(ADP-ribose) polymerase 1 (PARP1) 
and DNA polymerase θ (Pol θ) are important for a-EJ. F-G) Bloom syndrome RecQ-like helicase (BLM) 
and exonuclease 1 (EXO1) provide additional resection, and replication protein A (RPA) binds to ssDNA 
to promote the SSA and the HR pathways. RAD52-mediated annealing of large regions of homology is key 
for the SSA pathway. The xeroderma pigmentosum group F (XPF)–ERCC1 complex cuts the remaining 3ʹ 
overhangs before ligation. H) By contrast, RAD51-mediated strand exchange and its association with 
BRCA1, BRCA2 and RAD54 are essential for promoting the HR pathway. XLF, XRCC4-like factor; 
XRCC4, X-ray repair cross-complementing 4. Figure adapted and modified with permission from Chang, 
et al., (137).  
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1.5 Manipulation of the DNA Repair Systems. 
Precise genome editing not only requires the introduction of a DSB at an exact 
location in the genome, it requires the correct intended DNA repair outcome (18, 31). 
Inducing user-defined edits has become the major bottleneck in genetic engineering due 
to low rates of HR. Many efforts by several groups are taking place to increase HR rates, 
in general the strategies being taken can be classified into 4 groups: cell cycle 
synchronization strategies(158, 166), inhibition of the C-NHEJ repair pathway 
components(167-171), enhancement of the HDR pathway(172-174) and the rational 
design and use of ssODN donors, Cas9 and Cas9 variants(83, 84, 154, 164, 175, 176). 
 
An example for the cell cycle synchronization strategies is the work by Lin et al,. 
(177) were they reported that Nocodazole synchronization of HEK293T cells enhanced 
the total editing frequencies more than twofold and HDR frequencies over six-fold when 
transfecting variable doses of Cas9 ribonuceoprotein complexes and donors.  
 
Examples for the inhibition of the NHEJ is the use of the DNA-Ligase IV 
inhibitory compound SCR7. Chu et al., demonstrated  that SCR7 increased HDR (up to 
19-fold at a concentration of 1 µM ) (167), other reports indicate a very high variability of 
this molecule between different experimental systems (158); or even that SCR7 is neither 
a selective nor a potent inhibitor of the human DNA ligase IV (178). The use of the 
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adenovirus 4 (Ad4) proteins 4E1B-E4orf6, which mediate the ubiquitination and 
proteosomal degradation of DNA ligase IV have also been reported (167). The co-
expression of these proteins together with the CRISPR-Cas9 system using a 2A peptide 
was reported by Chu et al., (167) to improve HDR efficiency up to ~8-fold reaching HR 
frequencies of 50-66% and significantly decreased NHEJ activity in HEK293 and mouse 
Burkitt lymphoma-like cell lines. This same work reports the use of shRNA sequences to 
knock down KU70, KU80 or DNA ligase IV, which resulted in substantial suppression of 
the NHEJ and a ~5-fold improvement in HR. Following the same small molecule 
inhibition strategy, Robert el, al (170) reported the inhibition of the DNA-PKcs using the 
small molecules NU7441 and KU-0060648, which caused a decrease of ~40 % in NHEJ 
events with a ~2-fold increase in HDR, although HDR rates were low ~4 % HR; they also 
show the additive effect of combining these two compounds with either RS-1, SCR7, 
siRNA suppression of Ku70 and Ku80 and adenovirus proteins E1B55K and E4orf6, these 
last being the most efficient inhibiting NHEJ ~8-fold and stimulating HR ~3.5 fold, in line 
Chu, et al., (167). 
 
Examples for the enhancement of the HDR pathway is the use of RS-1 as a Rad51 
stimulatory molecule identified by a small molecule screen where it was shown to stabilize 
association of RAD51 with DNA(179). Rad51 is a key molecule in the HDR pathway that 
displaces RPA to form a RAD51–ssDNA nucleofilament recombinase, which is required 
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for homology search, strand invasion and ultimately the repair of the DSB lesion (148). 
Song et al.,(172) reported RS-1 improves HR rates 2-5 fold at a concentration of 7.5µM 
in vitro and in vivo (from 4.4 to 26.1%). RS-1 was also shown to improve HR rates in 
HEK cells (from 3.5 to 21%) at and U2OS cells (from 1.9 to 2.4%) at a concentration of 
10µM, but this varied depending on the locus and transfection method, with 
electroporation (~3-fold) having lower efficiency than with lipofectamine (~6-fold) (180). 
 
Finally, an example of the rational design strategies is the report by the Corn group 
(164). After investigating the interaction of Cas9 with target DNA they discovered that 
Cas9 releases the PAM-distal non-target strand after cleavage, but before complete 
dissociation. They used this finding to rationally design a ssDNA that matches this strand, 
they increased HR rates with up to 60% HR in the absence of any chemical intervention 
(164). Similarly, the group of Liang et al., used asymmetric ssODN with PS modifications 
that had up to 56% HR in HEK293 cells (181).  Another example is the work of  Gutschner 
et al., (158) where a 1.87-fold increase was obtained when fusing Cas9 to the N-terminal 
region of human geminin. This was adapted by another group where they recently 
indicated that a Cas9- GFP-geminin enhanced the HDR/NHEJ ratio 2.7 fold in U2-OS and 
1.8 fold in K562 cells and is now commercially available (182).  
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CHAPTER II  
THERAPEUTIC GENOME EDITING IN THE HORSE 
2.1 Abstract 
The Glycogen Branching Enzyme Deficiency (GBED) is caused by a nonsense 
mutation (C > A) in the first exon of the GBE1 gene that severely disrupts glycogen 
metabolism. This mutation is lethal in homozygotes and an estimated 9% of Quarter Horse 
and Paint Horse lineages are heterozygote carriers. Advances in the development of 
genome editing technologies have substantially improved our ability to make precise 
changes in the genomes of cells and gives us the opportunity to eliminate monogenic, 
highly penetrant diseases, such as the GBED mutation. To correct this mutation in a 
heterozygous cell line derived from a high genetic merit American Quarter Horse stallion, 
we used CRISPR-Cas9 to induce a double stranded break (DSB) to stimulate the DNA 
repair via homologous recombination (HR). The long-term goal is to use the corrected cell 
lines for somatic cell nuclear transfer (SCNT) by generating a cloned animal that 
maintains the genetic merit of its predecessor, but is free of the GBED mutation. To 
accomplish our objective, a series of sgRNAs flanking the mutation were cloned into the 
px458 plasmid (pSpCas9(BB)-2A-GFP), and then co-transfected with different single-
stranded oligodeoxynucleotide (ssODN) repair templates. Forty-eight hours post 
transfection, cells were enriched for GFP+ by flow cytometry and plated at low density 
for clonal isolation and expansion. Distal sgRNAs (+44, +15, -13) co-transfected with and 
  
 
32 
 
without a symmetrical repair template showed variable insertions and deletions (INDEL) 
formation (8.3% - 81.8% n=124) but no HR was observed. Proximal sgRNAs (+1, -1) co-
transfected with an asymmetric (67-30nt) ssODN with 5’ and 3’ phosphorothioate 
modifications showed 20.0% (n=20), and 23.1% (n=13) HR rates respectively. In order to 
decrease the possible number of off-target effects, truncated versions of these sgRNAs 
(+1T, -1T) were used, showing 4.3% (n=23) and 0.0% (n=13) HR, respectively. 
Interestingly, T-sgRNA -1 produced three HR positive colonies (20.0 %, n=15) when no 
repair template was present, this suggested that the homologous allele was used as the 
repair template. To verify this possibility, we targeted in an allele specific manner the non-
mutated allele and we obtained one colony homozygous for the mutation (7.7%, n=13). 
These results demonstrate that the CRISPR-Cas9 system can be used to correct the GBED 
mutation in primary equine cell lines, even in some instances, without the need for a repair 
template. 
 
2.2 Introduction 
Humans have been performing phenotypic genetic selection on plants and animals for 
centuries in order to suit their needs. Although this form of breeding has been successful 
in the establishment and improvement of many different breeds of plants and animals, we 
have unknowingly co-selected for deleterious alleles that have been propagating in animal 
populations (183). One of these deleterious alleles is the Glycogen Branching Enzyme 
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Deficiency (GBED) which is caused by a nonsense mutation (C > A) in the first exon of 
the GBE1 gene, that severely disrupts glycogen metabolism by decreasing the end points 
in the glycogen molecule for myophosphorylase to use as a substrate to liberate glucose 
(184). This mutation is lethal in homozygotes, due to the lack of GBE activity in liver, 
cardiac and skeletal muscle (184-187). An estimated 9% of Quarter Horse and Paint Horse 
lineages are heterozygote carriers, which have half of the normal tissue GBE activity (184-
187). This disease is also a significant cause of second and third trimester abortion and 
foal mortality in the Quarter horse breed (185, 188, 189). The majority of the Quarter 
Horses are descendants from two stallions and many of the GBED carriers can be traced 
to at least one of them: the sire King P234 (185). Other horse breeds like Thoroughbreds 
have been screened for GBED without finding this genetic mutation (185-187, 190).  
 
There are more than 6,052 identified genetic mutations linked to disease in humans 
and animals (191). Thanks to the advent of genome editing technologies based on 
programmable nucleases (31), it is now possible to make precise changes in eukaryotic 
genomes with the potential to correct monogenic diseases, such as the GBED mutation 
from affected cells(192), tissues(193) and eventually whole populations. This is the 
concept behind therapeutic genome editing, which arise out of the idea that instead of 
pursuing palliative care, the ideal therapy for monogenic diseases would be to develop a 
method that can directly correct the disease-causing mutations (194).  
34 
Since the early days of genome editing, it was realized that the precise targeting of a 
gene locus was hampered by the overall low frequencies, one per thousand transformed 
cells (0.001%) (11). However, this changed with the discovery of that a site specific double 
stranded break (DSB) in the DNA was the event that precipitated a particular locus to 
exchange genetic information with a homologous chromosome or provided repair 
template, a process known as homologous recombination (HR) (18). Since then, the field 
of genome editing has pursued the specific introduction of DSB at a particular locus with 
engineered nucleases (30): first with the zinc-finger nucleases (ZFNs) (31, 38), then 
transcription activator-like effector nucleases (TALENs) (42, 43), and more recently the 
CRISPR-Cas system (clustered, regularly interspaced, short palindromic repeats/CRISPR-
associated protein) (64, 72, 195). 
The CRISPR-Cas system was discovered as a natural adaptive immune system of 
prokaryotes, that protects them against the invasion of foreign viral nucleic acids (54). 
This biological discovery (44, 49-51) was subsequently engineered (64, 196, 197) as a 
precise and efficient genome engineering tool (72, 195, 198). The most commonly used 
Streptococcus pyogenes Cas9 (spCas9) is a type II CRISPR-Cas system (62) that uses a 
dual RNA molecule composed of the tracrRNA and the crRNA to create a double stranded 
break (DSB) at a precise location that matches the unique 20nt sequence in the crRNA, 
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requiring only the presence of a 5’-NGG protospacer adjacent motif (PAM). This dual 
RNA system, can be simplified for an engineered single chimeric small guide RNA 
(sgRNA) (64). After PAM recognition, Cas9 unwinds the DNA at the PAM-proximal 
region and creates a seed RNA-DNA heteroduplex pairing, then the R-loop propagates via 
sequential unwinding to the PAM-distal regions (162). Only when extensive pairing has 
occurred (on-target), Cas9 undergoes a conformational change in its HNH catalytic 
domain that triggers the RuvC catalytic domain activity ensuring a coordinated 
introduction of a DSB (163). While the HNH domain cleaves the gRNA complementary 
strand 3nt 5’ of the PAM, the RuvC domain cleaves of the non-complementary strand in 
a variable location due to the ability for this strand transition in and out of the nuclease 
domain (164). Finally, Cas9-DNA complex remains bound to the cleaved products for ~6h 
partially releasing the PAM-distal non-target strand before complete dissociation (163, 
165). Finally, DSBs are sensed by the cells endogenous DNA repair system (137, 139, 
141, 153) which repairs the DSBs predominantly by the canonical non-homologous end 
joining (c-NHEJ) pathway and to a lesser extent by the HR pathway, that comprises at 
least three sub-pathways: homology directed repair (HDR), single stranded annealing 
(SSA) and the recently recognized single stranded template repair (SSTR) (117, 146) 
(Figure 1). 
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There are many approaches for therapeutic genome editing in humans and animals. 
For example, by using somatic therapy, it is now possible to cure the acquired immune 
deficiency syndrome (AIDS), by taking a patient own CD4 T cells and using ZFNs to 
target the CCR5 gene that encodes a co-receptor required by most strains of HIV-1 to 
infect T cells(199, 200) and recently, the first chimeric antigen receptor (CART) T-cell 
gene therapy was approved by the FDA in the United States (201, 202). In addition, 
research for the germline genome editing of human embryos is taking place (203). But in 
the field of veterinary medicine, we have a unique and powerful tool that is not available 
in human medicine: reproductive cloning (204, 205). Producing cloned gene edited 
animals from edited cell lines has been successfully employed in the past (37, 110, 123, 
124, 205-215). More recently, hornless edited cattle were produced by the introgression 
of the polled gene into Holstein breed primary cells by using TALENs followed by 
reproductive cloning (216, 217).  
 
In this study, we utilized the CRISPR-Cas9 system to successfully correct for the 
first time, the GBED mutation in a heterozygous cell line derived from an American 
Quarter Horse stallion of high genetic merit. The long-term goal of our work is to use 
these corrected cell lines for somatic cell nuclear transfer (SCNT), generating a cloned 
animal that maintains the genetic merit of its predecessor, but is free of the GBED 
mutation (Figure 3).  
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2.3 Materials and Methods 
2.3.1 Primary Fibroblast Establishment and Culture 
A skin biopsy was collected in an aseptic manner under local anesthetic from an 
American Quarter Horse Stallion and donated to our laboratory by the horse owner. The 
sample was placed in 1x Ca and Mg free DPBS (Life Technologies®) and transported on 
ice. The sample was washed in a 0.2% (v/v) chlorhexidine gluconate in DBPS for 5 
seconds and then in two DPBS washes. The sample was placed in a 10 cm petri dish and 
it was cut into small pieces (<5 mm). The tissue sample was then washed through a series 
of DPBS washes in a 15 ml conical tube; for this, the sample was mixed by inverting the 
tube, the tissue was allow to briefly sediment and the supernatant media was aspirated. 
The tissue was re-suspended in Dulbecco’s Modified Eagle Medium with nutrient mixture 
F-12 (DMEM/F12) (Life Technologies®) supplemented with 10% fetal bovine serum 
(FBS), 1x antibiotic-antimycotic (Anti-Anti™, Thermo®) and 0.05mg/ml gentamicin (Life 
Technologies). The tissue sample was finally placed in a T25 tissue culture flasks (Falcon) 
and cultured at 37°C in a 5% CO2 and 5% O2 humidified incubator (Nuaire) to reduce 
oxidative stress and prolong the Hayflick limit. Cells were passaged when 80% confluence 
was reached, in a split ratio of no more than 1 to 3.  
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2.3.2 Karyotyping 
A normal karyotype integrity is essential for SCNT procedures (218). For this, 
primary and edited cell were sent for karyotypic evaluation to Dr. Terje Raudsepp at the 
Texas A&M Laboratory of Molecular Cytogenetics and Genomics. GTG-banding (G-
banding) was performed by trypsin treatment followed by Giemsa staining 
(Supplementary Figure 4).  
 
2.3.3 Short Guide RNA Design 
sgRNAs were designed using different bioinformatics web based tools follSowed 
by a manual sequence verification. The different programs used were the Broad institute 
CRISPRko which uses the on-target scoring described by Doench, et al., (219), and the 
WU-CRISPR tool of the Washington University described by Wong, et al., (220). All 
DNA sequences were manipulated using Benchling® (221) and APE. RNA folding was 
assessed using the Mfold web server for nucleic acid folding and hybridization prediction. 
Each guide and its complementary sequence was ordered as synthetic 25nmole oligos from 
Thermo® with attached BbsI cloning sites: Sense: 5’ – 
CACCGNNNNNNNNNNNNNNNNNNN – 3’ and antisense: 3’ – 
CNNNNNNNNNNNNNNNNNNNCAAA – 5’ (Figure 2, Supplementary Figure 1). 
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Figure 2. GBE Locus and CRISPR-Cas9 Targeting Strategy. 
Schematic illustration of the GBE1 locus with the different sgRNA/Cas9 targeting complexes used. The C 
to A mutation at base 102 is indicated by the black arrow; this mutation causes a premature stop codon 
(bottom). The Cas9 enzyme shown in blue is directed by the sgRNA (composed of the crRNA and the 
tracrRNA linked by a loop) is shown in red and the 20nt guide sequence in blue. Upstream of the guide 
sequence, lies the protospacer adjacent motif (PAM), shown in orange. Cas9 mediates the DSB 
approximately 3 bp upstream of the PAM, denoted by the red arrow heads for each guide used (i,e. +44, 
+15, +1, -1, -13).  
 
 
 
2.3.4 Short Guide RNA Cloning Into the PX458 Plasmid 
 The designed guides were cloned into the px458 (pSpCas9(BB)-2A-GFP) plasmid 
(Addgene, #48138). Synthetic oligonucleotides were suspended in water to 100µM and 
then 10µM of oligos was phosphorylated using T4 PNK (NEB) at 37°C for 1 hour. A 
0.5µM mix of both oligos, was annealed by heating at 95°C for 5 minutes, oligos were 
allowed to cool slowly at room temperature. The px458 plasmid was digested with fast 
digest BbsI (Thermo®) for 1 hour at 37°C, dephosphorylation was carried out with rSAP 
(NEB) for 30 minutes and the plasmid was run on a 1% agarose gel, followed by gel 
purification (Qiagen®). Ligation was performed with 50ng of the linearized vector and 1µl 
of the annealed oligos (0.5µM) using Quick ligase™ (Roche®) for 1h at room temperature. 
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One Shot TOP10 competent E. coli cells (Thermo®) were transformed following 
manufacturer instructions and plated in 100µg/ml Ampicillin (Sigma) LB agar plates 
followed by an overnight incubation at 37°C. Insert was verified by colony PCR using the 
sense oligo as a forward primer and a common Cbh reverse primer: 5’ 
GTCAATAGGGGGCGTACTTGG 3’, at a 50°C annealing using the HiFi PCR premix 
(Clonetech®). A Maxi prep (Qiagen®) was performed followed of a final verification by 
Sanger sequencing using the LKO forward primer for the human U6 promoter: 5’ 
GACTATCATATGCTTACCGT 3’.  
 
2.3.5 Repair Templates Design 
 All repair templates were designed by hand using the web application Benching. 
All single stranded oligonucleotide (ssODN) repair templates were ordered PAGE 
Ultramer® DNA Oligos from IDT® and suspended to a 100µM concentration in DNAse 
free water (Supplementary material 1). 
 
2.3.6 Transfection 
 In order to improve attachment and viability after transfection, plates were pre-
coated with 0.1% gelatin in 1xDPBS and incubated at 37°C for 1 h. Early passage cells 
were passed as described above and plated at density of 300,000 cells per well in a 6 well 
plate. Cells were cultured for at least 36h until an 80% confluence was reached. Cells were 
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transfected using Lipofectamine 3000™ (Thermo®). For this, each well was transfected 
with 1µg of CRISPR-Cas9 plasmid (Px458 with SgRNA) and 3µl of the 10mM ssODN 
(~600ng/µl). Media was replaced 12h after transfection. 
 
2.3.7 Flow Cytometry 
 After verifying GFP expression under an inverted fluoresce microscope (Nikon 
eclipse TE300) (Figure 4 B, C), cells were trypsinized and were suspended in transport 
media (10% FBS in DPBS, 1xAnti-Anti and 1mM EDTA). Cells were transported in ice 
to the Texas A&M CVM flow cytometry CORE facility. Before the flow sort, 2.5ng/ml 
of propidium iodide (PI) was added to the cells as a viability stain. Cells were sorted for 
single, PI - and GFP +. Cells were sorted into 45% FBS, 45% DMEMF12, 10% 
conditioned media from confluent healthy cells, 1x Anti- Anti and 100µM Y-27632, 
ROCK inhibitor (Stemcell®). Cells were plated at a density of 1000 cells per 150 mm dish 
for subsequent single cell colony isolation.  
 
2.3.8 Single Cell Colony Isolation 
After ~10 days of culture single cell colonies were recovered using agarose 
embedded cloning rings for single cell clone isolation as described by Mathupala, et al., 
(222). Briefly, single colonies were quickly marked with a permanent marker under a 
stereo microscope on the bottom surface of the plate. The plates were placed in the tissue 
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culture hood and cloning cylinders carefully placed around clones with sterile curved 
forceps; then one percent (w/v) LMP agarose (Sigma®) in 1xDBPS (37°C) was then 
slowly dispensed dropwise around the outside of the cloning cylinders. Cells were lifted 
with 40µl of 0.05% trypsin-EDTA (Invitrogen®) at 37°C for 5 minutes and then 100µl of 
normal culture media was added to inactivate the trypsin and pipetted several times to 
detach and suspend cells before moving each colony to a 48 well plate. Subsequent 
passages to larger wells were made as the cells became confluent. Cells from 6 well plates 
were passaged and half were frozen in 10% DMSO, 45% FBS, 45% DMEMF12 media 
using an isopropyl alcohol freezing container (Thermo®). The other half was used for 
DNA extraction.  
 
2.3.9 Colony Genotyping 
DNA was extracted using the DNeasy Blood & Tissue Kits (Qiagen®) with the 
addition of 1µl of tRNA (10µg/µl) for improved DNA yield. DNA was eluted in water 
and the concentration was measured using the nanoDrop™ spectrophotometer (Thermo®). 
PCR was performed with approximately 200ng of genomic DNA by using 2.5 units of the 
the HotStarTaq plus DNA polymerase (Qiagen®) with 1x Q solution, 100µM dNTpMix, 
and 0.1µM of each forward and reverse primers in a 50µl reaction. The PCR was run at 
an annealing temperature of 57oC with an extension time of 30s for 40 cycles. PCR 
products were purified using the QIAquick™ PCR purification kit (Qiagen®) and eluted 
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with water. Samples were sent to the Texas A&M Institute for plant Genomics and 
Biotechnology for Sanger sequencing reaction. Forward primer: 5’ 
CTCGCCGCTATAAAGGGCCCC 3’, reverse primer: 5’ TGCGCTGGAAGTCCGGGG 
3’. 
 
2.3.10 Sanger Sequencing Data Analysis.  
All chromatogram files were aligned in Benchling® (Supplementary Figure 2). 
The web application CRISPR-ID was used to de-convolute the overlapping spectra from 
the Sanger sequencing of PCR products. These overlapping spectra arise from the random 
C-NHEJ DNA repair of the CRISPR-Cas9 induced DSB. Because of the single cell origin 
of the colonies and the allele specific nature of the sgRNA (+15, +1, -1), the exact 
sequence of the resulting alleles can be identified using this tool. The sequence of a colony 
of sgRNA +15 with INDELS is shown (Figure 4, I). After de-convoluting the reads fasta 
files were converted manually to fastq files, then fastq groomer was run on galaxy before 
submitting them as single end reads to the web application CRISPResso, that was built for 
the analysis of CRISPR-Cas9 genome editing outcomes from deep sequencing data (223). 
The following parameters were used. Amplicon sequence: 
GCCGCCTTCTGGAGGTCGACCCGTAACTGAAGCCCTACGCCCCGGACTTCCA 
Expected HDR amplicon sequence:  
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GCCGCCTTCTGGAGGTCGACCCGTACCTGAAGCCCTACGCCCCGGACTTCCA. 
Sequence homology for an HDR occurrence: 95%, sgRNA sequence/s: 
GTAaCTGAAGCCCTACGCCC. Window size (bp around each side of cleavage site) to 
quantify NHEJ edits: 30 Exclude bp from the left side of the amplicon sequence for the 
quantification of the mutations: 5 Exclude bp from the right side of the amplicon sequence 
for the quantification of the mutations: Disabled (Supplementary Figure 3).  
 
2.3.11 Microsatellite Analysis and RT-PCR Taqman Assay.  
Genomic DNA from gene edited, non-carrier single cell colonies identified by 
Sanger sequencing and control carrier samples were sent for independent TaqMan DNA 
typing and carrier status verification to the Texas A&M Genetics Laboratory. A total of 
13 microsatellite markers (AHT4, AHT5, ASB17, ASB23, HMS6, HMS7, HTG4, 
VHL20, HMS3, ASB2, HTG10, LEX33 and HTG6) specific to Equus caballus were used 
(224, 225). All markers are included in the panel recommended by the International 
Society for Animal Genetics. GBED carrier status was determined by RT-PCR TaqMan 
Assay. Forward primer: CCTGGGCCGCCTTCT. Reverse primer: 
GCGCTGGAAGTCCGGG. VIC probe: CCCGTACCTGAAGCC. FAM probe: 
CCCGTAACTGAAGCC. 
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2.3.12 BAC DNA Isolation and BAC End Sequencing.  
 GBE1 containing BACs 93G22 and 112C9, verified by PCR, were set grown in 50 
ml tubes with LB media and chrloramphenicol overnight at 37oC in a shaker incubator. 
Two different kits were used: the Qiagen® midiprep and the PacBio® High Pure Plasmid 
Isolation kit with modifications. Briefly the Qiagen® kit manufacture instructions were 
followed with an isopropanol precipitation and resuspension performed instead of the 
filter based purification. The PacBio® kit was performed in triplicate combining the 
triplicate extraction in one column. DNA quality assessment was performed in gel and 
quantified in a NanoDrop™ spectrophotometer (Thermo®).  
 
 Bac end sequencing was performed in a 10.5µl reaction mix of 2 µl of Big Dye™, 
10 µM Primer, 1µl of BAC DNA and 10µl of MasterAMP™. The reaction was at 96oC for 
2 minutes, followed by 8 cycles of 96oC for 30s, 50oC 30s, 65oC 4 min, 60 cycles of 96oC 
30s, 50oC 30s, 60oC 4 minutes and 4 cycles of 96oC 1 min, 50oC 1min and 65oC for 15 
min. BioMax™ spin-50 columns were used to purified sequencing reactions and sent to be 
resolved in a sequencer. The following set of BAC end primers were used:  
 
TAMU and INRA M13 Reverse: 5’-CAGGAAACAGCTATGACC-3’ 
TAMU and INRA T7: 5’-TAATACGACTCACTATAGGG-3’ 
CHORI-241 T7-29: 5’-GCCGCTAATACGACTCACTATAGGGAGAG-3’ 
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CHORI-241 SP6: 5’- CCGTCGACATTTAGGTGACACTATAG-3’ 
2.3.13 Fluorescent In-Situ Hybridization.  
 Fluorescent in-situ hybridization (FISH) was performed with the help of Dr. Terje 
Raudsepp as described (226). Briefly, two slides one with the 93G22 BAC + 112C9 BAC 
isolated with the Genopure™ Plasmid Maxi Kit (Roche®) and the second with the 112C9 
BAC + 93G22 BAC isolated with the HiSpeed™ plasmid maxi kit (Qiagen®), were 
detected conjointly with the control probes ETSTY7 bio + ETSTY dig (Y chromosome) 
with 3 layers of avidin-FITC; biotinylated anti-avidin; avidin-FITC Digoxigenin – 1 layer 
of anti-dig Rhodamine. Both 93G22 and 112C9 map to the same (overlapping) region in 
chr26. Control probes mapped to the Y chromosome as expected. Both BACs 
corresponded to the region of interest. 
 
2.3.14 Statistical Analysis.  
All experiments were performed using three or more independent biological replicates. 
Unless otherwise indicated, statistical analyses of categorical variables were conducted 
using Pearson’s chi-square with Fisher’s exact test (227-229). For viability and 
fluorescence intensity analyses, after verifying for the assumptions of equal variance and 
normality, P values were calculated using One-Way ANOVA with Tukey’s HSD (230). 
Unless otherwise indicated, error bars represent standard deviation. Analyses were 
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performed with Prism™ (Graphpad®). Values with different subscripts are different 
(P<0.05). 
 
2.4 Results 
 
Figure 3.  Schematic Illustration of the Experimental Design. 
Schematic illustration of the experimental design. A skin biopsy was recovered from a high genetic merit 
American Quarter Horse stallion and a primary fibroblast cell line was established and cryopreserved. 
Different sgRNAs at a varying distance from the mutation were designed and cloned into the px458 plasmid 
(Addgene®) which allows for GFP selection. Different single-stranded oligo DNA (ssODN) repair templates 
(IDT®) were tested. Cells were co-transfected with the px458 plasmid and the repair template. Cells were 
incubated for 72H in four treatment groups. Cells were subsequently selected by flow cytometry for GFP 
positive and PI negative cells and plated at very low density in order to recovered single cell colonies. DNA 
was extracted for PCR amplification of the target region and sequenced for verification of the genetic 
correction. 
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We first established a karyotypically normal primary fibroblast cell line from an 
American Quarter Horse stallion (Figure 4 A) and a created a small bank of early passage 
cells. sgRNAs that flanked the mutation at a variable distance were designed (Figure 2) 
and cloned them into the CRISPR-Cas9 px458 plasmid (Addgene). Cells were transfected 
(Figure 4 B, C) and sorted by FACS for PI- and GFP+ cells (Figure 4 D). Cells were 
plated at low density and after ~10 days of culture, single cell colonies were recovered by 
using agarose embedded cloning rings, described in (222) (Figure 4 E, F). 
 
Due to the primary nature of our cells, the initial viability of the cells after FACS, 
measured as the number of total colonies divided by the number of plated cells was low 
6.96%±1.71 and was significantly lower 3.18%±0.89 (p<0.001) when a phosphorothioate  
(PS) modified ssODN was used but remained similar when a regular ssODN was used 
4.95%±0.73 (Figure 4 G). This decreased the number of colonies that could be sampled 
per replicate. The Rho-associated protein kinase (ROCK) among other functions activates 
the caspase signaling cascade leading to cellular apoptosis (231). To improve viability, we 
added 100µM of the Rho-associated protein kinase (ROCK) inhibitor (Y27632) to our 
recovery media and observed an approximate 6-fold increase in the number of viable 
colonies, for a total average viability post FACS of 16.03%±0.89 (Figure 4 H). 
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Figure 4. Primary Fibroblast Cell Line Establishment and Isolation of Single Cell Edited 
Colonies. 
A) Normal karyotype of equine primary fibroblasts. B) bright-field and C) fluorescent image 12h after 
transfection CRISPR-Cas9. D) fluorescent activated cell sorting (FACS) enrichment for GFP. E) Single cell 
colonies 15 days after of FACS, stained with Coomassie blue. F) Isolation of single cell colony after FACS 
enrichment and low-density plating. G) Phosphorothioate (PS) modified single-stranded 
oligodeoxynucleotide (ssODN) repair template decreased cell survival, but H) an apoptosis inhibitor (ROCK 
inhibitor Y27632) improves viability of cells. I) Chromatograph showing a shift in reading frame 4 bp 5’ of 
the PAM of sgRNA+15 demonstrating Cas9 mediated DNA allele specific cleavage. One way ANOVA, 
different letters signify statistical differences p < 0.05.  
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Figure 5. Gene Editing Outcomes from Designed sgRNAs. 
A) Indel formation of sgRNAs flanking the GBED mutation without a repair template. B) Total events with 
modifications and C) Percent of INDELS (p=0.5047) and HR (p=0.1256) of proximal sgRNAs (+1,+1T,-1,-
1T) and their truncated versions with an asymmetric ssODN. Values with different subscripts are different 
Chi-Square (P<0.05).  
 
 
 
 
Table 1. Distal sgRNAs With and Without a Symmetrical ssODN. 
 + ssODN RT  - ssODN RT 
sgRNA n Sequenced % INDEL % HR n Sequenced % INDEL % HR 
+44 16 18.8a 0.0 12 8.3 a 0.0 
+15 33 81.8b 0.0 28 85.7 b 0.0 
-13 19 15.8 a 0.0 16 18.8 a 0.0 
 
 
 
 
We observed variable sgRNA efficiency, with the sgRNA +15 being the most 
efficient and sgRNA +44, -13, +1, -1 showing similar level of activity (Figure 5A). Distal 
sgRNAs (+44, +15, -13) co-transfected with and without a symmetrical repair template 
showed variable insertions and deletions (INDEL) formation (8.3% - 85.7% n=124) but 
no HR was observed (Table 1).  
51 
Due to the high level of activity of sgRNA+15, together with the unidirectional 
characteristic of the INDEL tracts, that extended over the GBED mutation site 
(Supplementary Figure 2), we hypothesized that the use of the RAD-51 stimulatory 
compound RS-1 (15µM), the DNA-Ligase IV inhibitory compound SCR7 (80µM) or their 
combination with either the previously used symmetric ssODN (Table 2) or a silenced 
PAM ssODN (Table 3). No HR events obtained and similar INDEL rates were observed 
between groups. 
Table 2. RS-1 and SCR7 Effect on sgRNA +15 With ssODN. 
Treatment n Sequenced % INDEL % HR 
No Compound 33 81.8 0.0 
15µM RS-1 36 86.1 0.0 
80µM SCR7 43 79.1 0.0 
Combined 43 81.0 0.0 
Table 3. RS-1 and SCR7 Efect on sgRNA +15 With Mutated PAM ssODN. 
Treatment n Sequenced % INDEL % HR 
No Compound 17 70.6 0.0 
15µM RS-1 6 83.3 0.0 
80µM SCR7 10 90 0.0 
Combined 9 88.9 0.0 
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Figure 6. Sequence Verification of Genetic Correction of the GBED Mutation in Multiple 
Isolated Cell Lines.  
Subset of Sanger sequencing chromatograms of PCR fragments from the isolated single cell colonies. A) 
Control unmodified colony: red arrow indicates the double peak showing the C (blue) to A (green) 
conversion in one of the alleles, representing the heterozygous state of the horse. B), C) and D) subset of 
colonies of sgRNA +1, -1 and Truncated +1, respectively, with phosphorothioate modified single stranded 
oligonucleotide repair template (ssODN). E) Colony of truncated sgRNA -1 without a repair template. F) 
Colony of the truncated sgRNA targeting the WT allele without a repair template. In the corrected colonies 
(B-E) there is an absence of the double peak observed in the control colony (red arrows) and the height of 
the both adjacent cytosines read peaks is approximately the same, indicating the correction of the mutation 
in the mutated allele. 
 
 
 
 
 
Table 4. Proximal sgRNAs With and Without an Asymmetric PS-ssODN 
 + Asymmetric PS-ssODN  - Asymmetric PS-ssODN 
sgRNA n Sequenced % INDEL % HR n Sequenced % INDEL % HR 
+1 20 30.0 20.0 21 33.3 0.0 
+1T 23 30.4 4.3 7 57.1 0.0 
-1 13 15.4 23.1 8 37.5 0.0 
-1T 12 41.7 0.0 15 40.0 20.0 
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 CO-transfection of the proximal sgRNAs (+1, -1) with an asymmetric (67-30nt) 
ssODN with 5’ and 3’ phosphorothioate modifications (181) resulted in, 20.0% (n=20), 
and 23.1% (n=13) HR rates respectively Figure 5C, B). To decrease the possible number 
of off-target effects (232), truncated versions of these sgRNAs (+1T, -1T) were used, 
showing 4,3% (n=23) and 0.0% (n=13) HR, respectively (Table 4, Figure 4 C , B). 
Interestingly, T-sgRNA -1 produced three HR positive colonies (20 %, n=15) when no 
repair template was present. This suggested that the homologous allele was used as the 
repair template. To verify this possibility, we targeted, in an allele specific manner the 
non-mutated allele and we obtained one colony homozygous for the mutation (7,7%, 
n=13) (Table 5). No significant differences were found. Representative chromatograms 
are shown in Figure 6. 
 
Table 5. Targeting of the Wild Type Allele 
 - ssODN   
sgRNA n Sequenced % INDEL % HR % R 
WT 20 5.0 0.0 0.0 
WT - T 13 7.7 7.7 50.0 
 
 
Finally, analysis of sequencing chromatograms showed that INDEL tracts in the 
GBED locus were unidirectional, these tracts extended at least 50 bp from the DSB for 
sgRNA +15 and the INDELS introduced by Cas-9 were non-random with at least ~50% 
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of the events having a repeatable outcome (Supplementary Figure 2). Furthermore,  the 
allele specific nature of the proximal sgRNAs allowed us to do a more in-depth analysis 
of the genome editing outcomes by using the web application CRISPResso (223). We 
found on a subset of the events of sgRNA+1 (n=7), that 7.7% corresponded to HDR events 
together with some other mutation, and that the majority of the INDEL events were 
substitutions, followed by deletions and insertions (Supplementary Figure 3). 
 
2.5 Discussion 
Many genetic engineering strategies incorporate DSBs in close proximity to the target 
region to be repaired (233-235). This arose from the seminal study by Maria Jasin on DSB 
repair tracts (236), where it was reported that 80% of the repair tracts were ≤58bp. In 
primary equine fibroblasts, under the conditions of this study, only the sgRNAs targeting 
the mutation site in very close proximity (+1, -1) were capable of producing HR events 
(Table 4). This is in agreement with other published reports. However, at the GBE1 locus 
the allowable range for sgRNA recognition seems to be much narrower, as we did not 
obtain HR with sgRNA-guided Cas9-cutting greater than 13nt away from the mutation. 
For sgRNA -13, this could be due to the low DSB efficiency. We did not observe any HR 
events, even when we used a very active sgRNA (+15) with a symmetrical ssODN, PAM 
silenced ssODN.  
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The use of the RAD-51 stimulatory compound RS-1 (15µM) and the DNA-Ligase IV 
inhibitory compound SCR7 (80µM), at the concentrations tested, did not provide any 
benefit in improving HR rates (Table 2, 3). It is important to note that the concentration 
of SCR7 in the original publication of Chu, et al., had not been corrected at the time of the 
experiment. The concentration in the initial report of SCR7 was later corrected  to 1 µM 
(167), however this molecule has been highly controversial and other reports indicate a 
very high variability of this molecule between different experimental systems (158) or 
even that SCR7 is neither a selective nor a potent inhibitor of the human DNA ligase IV 
(178). In contrast, RS-1 as a Rad51 stimulatory molecule identified by a small molecule 
screen where it was shown to stabilize association of RAD51 with DNA(179). Rad51 is a 
key molecule in the HDR pathway that displaces RPA to form a RAD51–ssDNA 
nucleofilament recombinase, which is required for homology search, strand invasion and 
ultimately the repair of the DSB lesion (148). Song et al, (172) reported RS-1 improves 
HR rates 2-5 fold at a concentration of 7.5µM in vitro and in vivo (from 4.4 to 26.1%) . 
RS-1 was also shown to improve HR rates in HEK cells (from 3.5 to 21%) and U2OS cells 
(from 1.9 to 2.4%) at a concentration of 10µM, but this varied depending on the locus and 
transfection method(180). It is important to note that the HR repair with a ssODN has been 
recently referred to as single stranded template repair (SSTR) (117, 237) and it has been 
identified that is a RAD51/BRCA2 independent pathway (154) so the type of donor being 
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used is one of the possible explanations for why we did not observe any benefit of the RS-
1 molecule.  
 
In contrast to the work by Maria Jasin, Hollywood et al.; (238) reported that after 
analyzing CRISPR-Cas9 repair tracts in the human CFTR gene, they found that 90% of 
the editing events in the CFTR locus were long continuous repair tracts in excess of 100bp 
from the DSB with no bias towards bidirectional or unidirectional correction. With this 
finding, they created sgRNAs that induced a Cas9 DSB 100bp away from the target and 
obtained 1.9 % HR events when providing a repair plasmid that harbored seven nucleotide 
differences with ~2 kb homology arms. They suggest that there is a~200 bp window in 
which to select gRNAs for template-dependent editing. We found that INDEL tracts in the 
GBED locus were unidirectional, for sgRNA +15 which had a very high INDEL efficiency 
~85 % (Figure 4 A, Table 1), these tracts extended at least 50 bp from the DSB 
(Supplementary Figure 2). We were not able to employ long flanking homology arms 
because of the to the lack of the 3’ intronic sequence. Despite numerous attempts to either 
amplify or sequence from verified BAC clones, we were not able to characterize this 
sequence, possibly due to the high GC content surrounding this region. This illustrates the 
importance of well annotated and sequenced genome (239) for the successful gene editing 
of agricultural and companion animals.  
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The INDELS introduced by Cas-9 were non-random with at least ~50% of the events 
having a repeatable outcome (Supplementary Figure 2). This is in line with the work of 
Overbeek, et al., (240) where after studying the DNA repair patterns at 223 sites in the 
human genome they demonstrated that the distribution of INDELS resulting from repair 
of Cas9-mediated DSBs is nonrandom and is composed of contributions from the C-NHEJ 
and A-EJ pathway with the protospacer sequence and not the genomic context, 
determining the outcomes. Other studies (241) have found that HDR/NHEJ ratios were 
highly dependent on gene locus, nuclease platform, and cell type.  
 
A single stranded donor of an approximate length of 90nt was reported to produce high 
HR rates by Yang, et al., (234). This finding was later confirmed by the group of Liang, 
et al., (181), who reported that an asymmetric ssODN (67-30) with PS modifications had 
up to 56% in HEK293 cells. A mechanistic explanation was provided by Jacob Corn’s 
group. Which suggested that after investigating the interaction of Cas9 with target DNA, 
Cas9 releases the PAM-distal non-target strand after cleavage but before complete 
dissociation. They used this finding to rationally design an asymmetric ssDNA that 
matches this strand, they increased HR rates with up to 60% HR in the absence of any 
chemical intervention(164) 
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In our work, to improve viability, we added 100µM of the Rho-associated protein 
kinase (ROCK) inhibitor (Y27632) to our recovery media and observed an approximate 
6-fold increase in the number of viable colonies, for a total average viability post FACS 
of 16.03%±0.89.  Other groups have reported that in primary porcine cells, without the 
combined use of a p53 inhibitor, PFTα, and a growth factor, bFGF, it was not possible to 
isolate single cell modified colonies(119). 
 
Besides the proximity and type of repair template, another, and much more interesting 
possibility for the lack of HR with the distal sgRNAs at the GBE1 locus, is the genomic 
context and the chromatin state at this locus. It has been shown that Cas9 diffusion and 
chromatin binding is reduced but not eliminated at heterochromatic regions (242) and that  
nucleosomes, in fact, directly impede Cas9 binding and cleavage, while chromatin 
remodeling can restore Cas9 access (243). Miyaoka et al., showed that depending on the 
genomic context more HDR than NHEJ can be induced and viceversa (241). The repair of 
the DSB is also influenced by the chromatin context, although the repair of 
heterochromatic DSB is just starting to be understood, it is known that pericentrometric 
heterochromatin relies on the relocalization of repair sites to the nuclear periphery before 
Rad51 recruitment and repair progression (150, 151). Due to the tissue specific expression 
of the GBE1 enzyme, is likely that in primary fibroblast, this gene is silenced, which is 
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normally enriched with marks like H3K27me3 that are associated to the lamina-associated 
domains (LADs) for which DNA DSBs repair mechanisms are still unknown. 
 
2.6 Conclusions 
In conclusion, we were able to correct the GBED mutation with moderate efficiency 
(~20%) when using proximal sgRNAs cutting within 1 nucleotide of the intended 
correction site. We have also shown that sgRNA INDEL efficiency does not always 
correlate with the incorporation of HR events, even in the presence of small molecule 
compounds that have been reported to improve HDR. We showed that INDELS resulting 
from repair of Cas9-mediated DSBs are nonrandom and unidirectional in the GBE1 locus. 
Finally, we show that in rapidly dividing equine fibroblasts, when using allele specific 
sgRNAs, the use of the homologous chromatid for the repair of a DSB can be more 
common than we initially thought.  
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CHAPTER III  
IMPROVING THE EFFICIENCY OF HR USING C16 
 
3.1 Abstract 
Precise genome editing requires the introduction of a double stranded break (DSB) at 
an exact location in the genome and the correct DNA repair outcome. Although CRISPR-
Cas9 has allowed for the introduction of precise DSBs in a very efficient manner, the lack 
of control over cell-autonomous repair mechanisms namely non-homologous end-joining 
(NHEJ) and homologous recombination (HR), is still the major bottle neck for seamless 
genome editing. The DNA-dependent protein kinase (DNA-PK), composed of the Ku 70 
- Ku 80 heterodimer and the DNA-PK catalytic subunit (DNA-PKcs), is best known as the 
NHEJ molecular sensor for DNA damage, but has been also identified as a pattern 
recognition receptor (PRR) that defends against the invasion of foreign nucleic acids 
(244). Here we devised a novel strategy that capitalizes on the natural ability of the 
vaccinia virus (VACV) C16 protein that evolved as an elegant subversion mechanism to 
inhibit the detection of the VACV genome by the host cytoplasmic PRR defenses, 
specifically the Ku-mediated DNA sensing (245). We evaluated the effects of this protein 
in a HEK293 BFP to GFP conversion assay. By localizing C16 into the nucleus we were 
able to obtain a ~ 2-fold increase (~10% HR) for HDR rates when they were low (~5% 
HR). After optimization of our assay for higher HR rates (~20% HR) we no longer saw a 
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benefit, and we believed were masked by the optimized conditions and the use of a ssODN 
that uses the SSTR and not the HDR pathway for repair. Future spatiotemporal 
refinements of this protein may enable highly efficient genome editing. 
 
3.2 Introduction 
The CRISPR-Cas system (clustered, regularly interspaced, short palindromic 
repeats/CRISPR-associated protein) was discovered as a natural adaptive immune system 
of prokaryotes that protects against the invasion of foreign viral nucleic acids (54). This 
biological discovery (44) was subsequently engineered (64, 196, 197) as a precise and 
efficient genome engineering tool (72, 195, 198). The most commonly used Streptococcus 
pyogenes Cas9 (spCas9) is a Type II CRISPR-Cas system (62) that uses a dual RNA 
molecule composed of the tracrRNA and the crRNA, to create a double stranded break 
(DSB) at a precise location. The target, matches the unique 20nt sequence in the crRNA, 
requiring only the presence of a 5’-NGG protospacer adjacent motif (PAM). This a dual 
RNA system, can be simplified for an engineered single chimeric small guide RNA 
(sgRNA) (64). After PAM recognition, Cas9 unwinds the DNA at the PAM-proximal 
region to create a seed RNA-DNA heteroduplex pairing. Next, the R-loop propagates via 
sequential unwinding to the PAM-distal regions (162). Only when extensive pairing has 
occurred (on-target), Cas9 undergoes a conformational change in its HNH catalytic 
domain that triggers the RuvC domain catalytic activity ensuring a coordinated 
  
 
62 
 
introduction of a DSB (163). While the HNH domain cleaves the gRNA complementary 
strand 3nt 5’ of the PAM, the RuvC domain cleaves the non-complementary strand in a 
variable location due to the ability for this strand to breathe in and out of the nuclease 
domain (164). Finally, Cas9-DNA complex remains bound to the cleaved products for ~6h 
partially releasing the PAM-distal non-target strand before complete dissociation (163, 
165). These DSBs are then identified by the cell’s endogenous DNA repair system (137, 
139, 141, 153) (Figure 1 A-C). 
 
DSBs are the most dangerous type of DNA damage, which if left unrepaired, can result 
in chromosomal translocations, the loss of large chromosomal regions or can activate cell 
cycle check-point arrests that can induce signals for programmed cell death. In dividing 
mammalian cells, there are an estimated ten DNA double-strand breaks (DSBs) per day 
per cell (137). These pathological DSBs arise from DNA replication errors, reactive 
oxygen species, and genotoxic agents such as ionizing radiation, radiomimetic chemicals 
or topoisomerase inhibitors (138). There are also physiological DSBs that arise during 
normal cellular processes, such as meiosis, V(D)J recombination and class-switch 
recombination (CSR) which facilitate the rearrangements of antigen receptor genes in 
lymphogenesis (137, 138) (Supplementary Figure 14).  
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Organisms have evolved sophisticated DNA damage response pathways that sense the 
DNA lesion and activate repair mechanisms to correct the genomic insult (153, 154). 
DSBs are repaired predominantly by the canonical non-homologous end joining (c-NHEJ) 
pathway that is present throughout the cell cycle with peak activity during the G1, S and 
G2 phases (139). This is the main repair pathway due to the high abundance of the Ku70 
and Ku80 molecules in cells (137), which increases the likelihood that the Ku-heterodimer 
is the first protein to bind the broken DNA ends, and therefore repair is carried out through 
NHEJ. This pathway can either result in a perfect repair by ligation of the two ends, or 
depending on the degree of microhomology (≤4 nucleotides) between the ends (112), 
different repair sub pathways are directed that can create multiple rounds of end resection 
and addition. This is a very error-prone process that can result in diverse DNA sequences 
at the repair junction, here on referred to as insertions and deletions (INDELS) (114-116).  
 
A subset of the DSBs undergo 5ʹ to 3ʹ endo- and exo-nucleolytic processing by the 
carboxy-terminal binding protein interacting protein (CtIP) and the MRN (MRE11–
RAD50–NBS1 (Nijmegen breakage syndrome protein 1)) complex, which lead to the 
generation of stretches of single-strand DNA (ssDNA) 3’ overhangs. This is a very rapid 
(~30 minutes) (143) and highly regulated process, controlled by the cell cycle cyclin-
dependent kinases (CDKs) (137). These 3’ overhangs are suitable substrate for two 
possible mechanisms: alternative end joining (A-EJ, also known as micro homology-
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mediated end joining (MMEJ), Pol θ-mediated end joining or alternative NHEJ), which 
uses small sequence homologies (~2-20 nt) and the homologous recombination (HR) 
pathway, which relies on extensive homology (~20 - >100 nt). Neither pathway is reliant 
on Ku, and the binding of Ku to DNA ends may need to be attenuated for a-EJ and HR to 
proceed (112).  
 
The HR pathway comprises at least three sub-pathways: homology directed repair 
(HDR), single stranded annealing (SSA) and the recently recognized single stranded 
template repair (SSTR)(117, 146). HR is slow (~≥7h), but is normally an error free process 
that uses the sister chromatid for repair during the late S and G2 phases of the cell 
cycle)(143). Mechanistically, replication protein A (RPA) binds to the ssDNA 3’ ends and 
subsequently, BRCA2 recruits the RAD51, which displaces RPA to form a RAD51–
ssDNA nucleofilament recombinase. This nucleofilament is required for homology 
search, strand invasion and ultimately the repair of the lesion (148). For heterochromatic 
regions that can engage in ectopic recombination during DSB repair, leading to 
chromosome rearrangements and widespread genome instability, the HDR repair relies on 
the relocalization of the DSBs to the nuclear periphery before Rad51 recruitment(150, 
151). Single-strand annealing, in contrast, mediates annealing between stretches of 
chromosome-internal homologies resulting in the loss of the intervening region, and is 
therefore considered an error prone repair pathway (117, 137, 147, 152, 153). Single 
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stranded template repair has not been fully characterized to date but is known to require 
multiple components of the Fanconi Anemia (FA) pathway but is independent of BRCA2 
or Rad51 (146, 154) (Figure 1 D-H). 
 
Precise genome editing not only requires the introduction of a DSB at an exact location 
in the genome but most importantly, requires the correct intended DNA repair outcome 
(18, 31). Inducing user-defined edits has become the mayor bottleneck in genetic 
engineering due to low rates of HR occurrence. Many efforts by several groups are taking 
place to increase HR rates. In general the strategies being taken can be classified into 4 
groups: cell cycle synchronization strategies (158, 166), inhibition of the C-NHEJ repair 
pathway components(167-171), enhancement of the HDR pathway (172-174) and the 
rational design and use ssODN donors, Cas9 and Cas9 variants (83, 84, 154, 164, 175, 
176, 246). There has been only moderate success and HR rates over 50% have just been 
recently been achieved (154, 167). It is likely that the best HR rate improvements will be 
achieved using combinatorial approaches, employing many of these strategies (247).  
 
It is well documented that viruses have evolved proteins that counteract host detection 
mechanisms by binding and inhibiting signaling molecules. The DNA-dependent protein 
kinase (DNA-PK) , composed of the Ku 70 - Ku 80 heterodimer and the DNA-PK catalytic 
subunit (DNA-PKcs), is best known as the molecular sensor for DNA damage(137) and 
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was recently identified as a pattern recognition receptor (PRR), which activates the innate 
immune response against DNA viruses(244, 245). As such, viruses have evolved strategies 
to inhibit host defense mechanisms and circumvent detection. The Vaccinia virus (VACV) 
is a dsDNA virus that is a member of the genus Orthopoxvirus and of the family 
Poxviridae, and is best known to be the live vaccine used to eradicate smallpox (248). The 
VACV encodes numerous proteins that inhibit the host innate immune system and 
reprogram cellular biochemistry to favor viral replication in the cytoplasm (245, 249). The 
C16 protein evolved as an elegant subversion mechanism to inhibit the detection of the 
VACV genome by the host cytoplasmic pattern recognition receptors (PRRs) defenses, 
specifically the KU-mediated DNA sensors (245). This results in the inhibition of the 
assembly of the DNA-PK complex and its stimulation of the innate immune pathway(245) 
(Figure 1 D).  
 
In this study, we generated a novel genetic engineering strategy that capitalizes on the 
natural ability of the vaccina virus C16 protein to inhibit the binding of the KU 
heterodimer molecules. In these experiments, we hypothesize that we could re-localize 
C16 from the cytoplasm to the nucleus and use it to interfere with the C-NHEJ pathway 
by obstructing the KU-mediated DNA DSB sensing and subsequent DNA-PKCS 
recruitment (245). We show the importance of the spatiotemporal expression of C16 with 
respect to CRISPR-Cas9 for its activity. Our findings show that C16 can be used to 
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enhance HDR rates up to 2-fold, and future spatiotemporal refinements may enable a more 
efficient genome editing.  
 
3.3 Materials and Methods 
3.3.1 Vector Design  
In order to compartmentalize C16 in the nucleus and assess its efficiency, we 
generated a mCherry fusion construct that allowed for different plasmid versions to be 
generated by standar molecular cloning. For this, the 311aa protein coding sequence of 
the Vaccinia virus (VACV) strain Western Reserve (WR) C16 protein (GenBank: 
AGJ92502.1) and its cDNA sequence was determined by using the NCBI GenBank®. All 
the DNA sequences were worked using Benchling®. Codon optimization for homo sapiens 
was made by using the IDT codon optimization software. Correct translation of the 
constructs was made by using the ExPASy® translate tool software. In order to create a 
nuclear compartmentalization of C16, 3 repeats of the nuclear localization signal 
(DPKKKRKV) were attached to either the N or C terminus of the fusion protein with 
either Bglll and KpnI flanking sites respectively. In order to visualize the nuclear 
compartmentalization of the C16 protein, a fusion protein was made by attaching codon 
optimized mCherry protein to the C terminus of the C16 protein by a Gly4Ser2 linker 
flanked with EcoRI sites. The sequence was ordered as synthetic vector from Vector 
Builder® (Figure 7). 
68 
In order to create the different variants of the C16 vector (Vector Builder®) 
described above, (Figure 7, A-G) standard molecular cloning was used. For this a total of 
1 µg of DNA of the C16 vector (986 ng/µl) was digested using either Kpn I or Eco RI in 
CutSmart™ buffer (NEB®) or Bgl II in buffer 3.1™ (NEB®) and the reaction was 
incubated at 37ºC during 3 hours. Digest products that were going to be double digested 
(Bgl II digest of KpnI digest product and Eco RI of Kpn I digest product) were purified 
with the QIAquick™ PCR purification kit (Qiagen®). The digested products were run on 
a 0.5% agarose (Invitrogen®) gel during 3h at 90V, appropriate bands were cut 
(Supplementary Figure 5, 6) and purified using the QIAquick™ gel extraction kit 
(Qiagen®). All DNA concentration in samples were measured using NanoDro™ 
spectrophotometer (Thermo Scientific®).  
The ligation of ends was made as follows, in order to calculate the amount of vector 
and insert needed, the molarity of ends for both with a 3:1 ratio was calculated (Molarity 
= [(µg/µl) ÷ (base pairs x 650 daltons)] x 2 ends), the ligation was made with using the 
Rapid DNA Ligation kit (Roche®) in a 21µl total volume. One Shot™ TOP10 Chemically 
Competent E. coli (Invitrogen®) were transformed using 2µl of the ligation reaction. 
Briefly, the ligated DNA was chilled on ice for 5 minutes, 25µl previously ice-thawed One 
Shot™ TOP10 Chemically Competent E. coli (Invitrogen®) was gently added to the DNA, 
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the mixture was incubated for 30 minutes on ice, then the bacteria were subjected to a heat 
shock at 42 ºC for 30 seconds and returned to ice for 2 minutes, 300µl of S.O.C media 
(Invitrogen®) was gently added and the bacteria was incubated at 37ºC in a shaking 
incubator during 1 hour, and transformed cells were plated down in 100µg/ml ampicillin 
(Sigma®) LB - agar plates. After a 12h incubation at 37ºC colonies were selected and 
inoculated in 5 ml of LB-Broth with 100µg/ml of Ampicilin, incubated overnight in a 37ºC 
shaking incubator. The plasmid DNA was purified using a QIAprep™ miniprep Kit 
(Qiagen®) following manufacture instructions. DNA concentration was measured using 
NanoDrop™ spectrophotometer (Thermo Scientific®). 
 
 A restriction fragment analysis was made in order to verify the sequence of the 
corrected clones, once verified we proceeded to do a maxi prep isolation of the plasmid 
DNA for each of the variants of the C16 constructs using the DNA HiSpeed Plasmid Maxi 
kit (Qiagen®). DNA concentration was measured and concentrated up to 1µg/µl using a 
SpeedVac concentrator (Thermo Scientific®). All isolated vectors (Figure 7) were verified 
by Sanger sequencing using the primers listed in (Supplementary table 1); alignment is 
shown in (Supplementary Figure 7). 
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3.3.2 Generation of HEK293 BFP Cell Line 
In order to create a genetically modified cell line with a unique genomic integration 
of the blue fluorescent protein gene (BFP), lentiviral particles expressing BFP and 
puromycin under the EF1a and SV40 promoters respectively were used (Sigma®).For this, 
HEK 293T cells were seeded at 3 x 105 cells/well in 6-well plates and maintained for 18 
h and the supernatant was then replaced with 1 ml of antibiotic free 20% FBS DMEM-12 
with 100µM Y-27632, 8µg/ml hexadimethrine bromide and diluted lentiviral particles 
containing 3 x 105 TU/ml, 1.5 x 105 TU/ml, 3 x 104 TU/ml, for a MOI of 1, 0.5 and 0.1 
respectively, followed by incubation overnight1. 48h post-transduction cells were analyzed 
and sorted by flow cytometry for BFP+ and PI- into 96 well plates and 5 ml tubes 
(Supplementary Figure 8). 
  
To identify the best concentration of puromycin to make a gradual selection to 
insure high levels of the transgene expression, HEK 293 were cells seeded in a 48 well 
plate at a concentration of 5 x 104 cells per well. Puromycin dihydrichloride (Thermo®) 
stocks were made in water to a concentration of 1mg/ml. Puromycin stocks were diluted 
1.5ml of media for testing a range of concentrations (10,8,6,4,2,1,0.1,0 µg/ml) in triplicate 
wells. Cells were analyzed for cell dead by FACS 48h after the treatment. Transduced 
HEK 293 T cells were subject to a gradual puromycin selection starting at 0.5µg/ml 48h 
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after flow cytometry up to 2µg/ml changing the media every 72h in 0.5µg/ml increments 
(250). 
 
A commonly encountered problem in cell lines produced by lentiviral transduction 
is heterogeneity expression of the vector-encoded transgene obtained in cell populations; 
this is due to copy number and position effects conferred by different integration sites 
(250, 251). Furthermore, retroviral vectors are often subject to transcriptional silencing 
shortly after transduction or extinction (progressive silencing of an initially expressing 
vector), through known mechanisms of gene repression, such as DNA methylation and 
histone modification, as well as through uncharacterized mechanisms. In order to have a 
homogenous expression cell line, the HEK 293T cells originally transduced with 1.5 x 105 
TU/ml, sorted and subject to gradual puromycin selection, were subject to a second round 
of flow cytometry were cells were gated for a homogenous medium - to high expression 
of the BFP transgene (Supplementary Figure 8, B). Sorted cells were recovered, 
expanded and cryopreserved.  
 
 To have an accurate targeting of the BFP sequence, a PCR reaction was performed 
with the following primers: Forward 5’ CCTGAAGTTCATCTGCACCACC 3’, Reverse 
5’ CCATGCCCGAAGGCTACGTC 3’; using the CloneAmp™ HiFi PCR Premix 
(Clonetech®). Samples were sent to the Laboratory for Plant Genome Technologies 
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(LPGT) from the Institute for Plant Genomics and Biotechnology of Texas A&M 
University.  
 
3.3.3 ddPCR for Copy Number Quantification of GFP Transgene  
DNA samples were taken to the Texas A&M Institute for Genome Science and 
Scociety. Briefly, the ddPCR Master mix was performed following the manufacturer 
instructions using a reaction mixture in a final volume of 20 µL with 20 ng of the genomic 
DNA as the template. Restriction digest was performed in the ddPCR reaction using the 
enzyme HAEIII (NEB). Each reaction mixture was then loaded into a DG8 cartridge (Bio-
Rad) with 70 µL of droplet generation oil to generate a droplet. The droplets from each 
well were then transferred into a 96-well PCR plate. The plates were heat-sealed and then 
thermally cycled under the following conditions: 37°C for 20 min (one cycle), 95°C for 
10 min (one cycle); 40 PCR cycles of 94°C for 30 seconds and 60°C for 1 min; followed 
by one cycle of 95°C degrees for 10:00 minutes and a hold at 4°C. After PCR, the plates 
were placed on a QX200 droplet reader (Bio-Rad®) that analyzed the droplets of each well 
of the plate and quantified the target DNA. The PCR data were analyzed using QuantaSoft 
(Bio-Rad®) to determine the copy number variation (CNV). Copy numbers were 
calculated based on droplet numbers of the target, (BFP) compared to the single copy 
reference (RPP30) (e.g. BFP/RPP30: ∼ 1 = Mono-allelic, ∼ 2.0 = Bi-allelic, ∼ 3.0 = Tri-
allelic). Data represents two HEK 293 negative controls and four technical replicate 
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samples of genomic DNA extracted from FACS sorted GFP+ cells together with a no 
template control (NTC) as a negative control (Supplementary Figure 9). 
  
3.3.4 Short Guide RNA Design and Cloning  
 sgRNAs Targeting the BFP protein chromophore region were designed using 
Benchling®. Each guide and its complementary sequence was ordered as synthetic 
25nmole oligos from Thermo fisher® with attached BbsI cloning sites: Sense: 5’ – 
CACCGNNNNNNNNNNNNNNNNNNN – 3’ and antisense: 3’ – 
CNNNNNNNNNNNNNNNNNNNCAAA – 5’ (Supplementary Table 2). 
 
In order to clone the designed guides into the pU6-(BbsI)_CBh-Cas9-T2A-
mCherry plasmid (Addgene®), synthetic oligos were suspended in water to 100µM and 
then 10µM of oligos was phosphorylated using T4 PNK (NEB) at 37°C for 1 hour. A 
0.5µM mix of both oligos, was annealed by heating at 95°C for 5 minutes, oligos were 
allowed to cool down slowly at room temperature. The pU6-(BbsI)_CBh-Cas9-T2A-
mCherry plasmid was digested with fast digest BbsI (Thermo®) for 1 hour at 37ºC, 
dephosphorylation was carried out with rSAP (NEB) for 30 minutes and the plasmid was 
run on a 1% agarose gel, followed by gel purification (Qiagen®). Ligation was performed 
with 50ng of the linearized vector and 1µl of the annealed oligos using Quick ligase 
(Roche) for 1h at room temperature. One Shot TOP10 competent E. coli cells (Thermo®) 
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were transformed following manufacturer instructions and plated in 100µg/ml Ampicillin 
(Sigma) plates followed by an overnight incubation at 37°C. Insert was verified by colony 
PCR using the sense oligo as a forward primer and a common Cbh reverse primer: 5’ 
GTCAATAGGGGGCGTACTTGG 3’, at a 50°C annealing using the HiFi PCR premix 
(Clonetech®). A Maxi prep (Qiagen®) was performed, followed of a final verification by 
Sanger sequencing using the LKO forward primer for the human U6 promoter: 5’ 
GACTATCATATGCTTACCGT 3’. 
 
3.3.5 Electroporation 
In order to achieve high editing rates, we used the Neon™ electroporation system 
(Thermo®) manufacturer instructions for program optimization (Supplementary Figure 
10). HEK293 cells were trypsinized and centrifuged at 250×g for 5min, the supernatant 
was carefully aspirated and the cell pellet was suspended once with 10 mL of DPBS 
without Ca2+ and Mg2+, a 10µl sample was mixed 1:1 with 0.4% trypan blue and cell 
concentration was quantified in a Countess® automated cell counter (Thermo®). The 
sample was centrifuged again and the supernatant was carefully aspirated and the cell 
pellet was suspended in Buffer R to a final concentration of 5 x 105 cells/µl. DNA plasmids 
(i.e 750ng pU6-BFP-sgRNA#1_CBh-Cas9-T2A-mCherry, 750ng C16 vector) and repair 
template (500ng of ssODN) were diluted in R buffer up to 9µl. A 24µl cell suspension 
mix for two reactions was made with 15µl of the cell suspension mix and the 9µl of the 
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DNA mix. The parameters used for electroporation were: tree pulses of 1500 v with a 
10ms width. The electroporated cells were transferred to a 25cm Nunc™ Cell Culture 
Treated EasYFlasks™ (Thermo®) with 4ml of antibiotic free 20% FBS DMEM-F12 with 
10µM Y-27632 followed by incubation for 48h in a 5% CO2 humidified incubator before 
replacing the media for 10% FBS DMEM-F12 1xAnti-Anti (Thermo®) with 2µg/ml of 
puromycin. For the compound treatments media was replaced 24h after electroporation 
with the compounds (i.e 15µM RS-1 and 80µM SCR7) and incubated for 72h before 
replacing the media. For the two electroporations, 100µl tips were used with the same 
propotions of DNA, but using an in-house made buffer (SBB: 250 mM sucrose and 1 mM 
MgCl2 in 1x DPBS) as reported by Brees et al., (252). All tips were recycled as reported 
by Brees et al., plus overnight UV incubation. 
 
3.3.6 Nuclear Re-Localization of C16 From the Cytoplasm to the Nucleus 
In order to evaluate the nuclear compartmentalization of C16, HEK 293 cells were 
electroplated as described above with the isolated vectors that contained a fused mCherry 
gene for visualization (Figure 8, A-D). Cells were imaged under an inverted fluoresce 
microscope (Nikon eclipse TE300) and mean grey value was quantified using Adobe 
Photoshop CC 2017 (Figure  8). 
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3.3.7 Flow Cytometry for BFP to GFP Analysis 
In order to quantify editing outcomes, transfected cells were analyzed by flow 
cytometry after 8 days of culture. Cells were transported in 10% FBS 1x PBS and 1mM 
EDTA. Cell were gated for single cells and a total of 20,000 single cell positive events 
(GFP+) were collected. Analysis was performed in FlowJo. Statistical analysis was 
performed in Prism (Figure 9). 
 
3.3.8 Statistical Analysis 
All experiments were done with two or more independent biological replicates each 
with two or more technical replicates. Only the means of the biological replicates are used 
for the analysis (253). Unless otherwise indicated, after verifying for the assumptions of 
equal variance and normality, P values were calculated using One-Way  ANOVA with 
Tukey’s HSD (230). Unless otherwise indicated, error bars represent standard deviation. 
Analyses were performed with Prism (Graphpad®).  
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3.4 Results 
Figure 7. C16 Designed Vector and Variants. 
Schematic illustration of the designed vector. A) Complete synthetic gene with two 3xNLS in the C and N 
terminus. B) Synthetic gene with no NLS produced from a Bgl II and KpnI digestion. C) Synthetic gene 
with N terminus 3xNLS produced from a KpnI digestion. D) Synthetic gene with C terminus 3xNLS 
produced from a Bgl II digestion. E) C16 protein with both N and C terminus 3xNLS. F) C16 protein with 
N terminus 3xNLS. G) C16 protein with C terminus 3xNLS. G) C16 protein with C terminus 3xNLS. G) 
C16 protein with no NLS. 
Figure 8. Nuclear Localization Assessment of C16. 
Brightfield and fluorescence imaging for mCherry and Hoechst. A) C16-mCherry fusion gene with no NLS. 
B) Complete synthetic gene with two 3xNLS in the C and N terminus. C) Synthetic gene with N terminus
3xNLS. D) Synthetic gene with C terminus 3xNLS. Values with different subscripts are different, 
nonparametric One-Way ANOVA (Kruskal-Wallis) test, p<0.05, error bars represent standard error of mean 
(SEM). 
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3.4.1 Nuclear Re-Localization of C16 From the Cytoplasm to the Nucleus 
We designed a vector carrying the codon optimized C16 protein fused to a C 
terminus mCherry via a GS linker with two 3xNLS on both the N or C Terminus (Figure 
7, A). We then constructed different versions of this vector with and without mCherry, 
carrying either a N or C terminus NLS or no NLS at all (Figure 7, B-H). The mCherry 
fusion constructs were transfected into HEK293 cells, and nuclear localization was 
quantified as the mean grey value in the nuclear area determined by Hoechst stain (Figure 
2). The presence of the 3 repeats of the NLS were able to re-localize C16 form the 
cytoplasm (Figure 8 B) to the nuclear compartment (Figure 8A, C and D) independently 
of the location. Nevertheless, the mean grey value (fluoresce) was significantly lower 
(p<0.05) with the presence of the NLS in both terminus (Figure 8, A) or in the N termini 
(Figure 8, C) compared to the wild type protein (Figure 8, B). The highest nuclear 
fluorescence was obtained in the C16 protein carrying a C terminus NLS (Figure 8 D). 
3.4.2 Establishment of BFP to GFP Conversion Assay in HEK293 Cells 
To evaluate the CRISPR genome editing outcomes we first generated a modified 
HEK293 cell line with single genomic integrations of a lentiviral transgene crrying the 
blue fluorescent protein gene (BFP), BFP and puromycin resistance cassette gene under 
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the EF1a and SV40 promoters respectively, using lentiviral particles. This cell line was 
sorted twice by flow cytometry (Supplementary Figure 8). Transgene copy number was 
determined using ddPCR, resulting in BFP/RPP30: ∼ 3 (tri-allelic, 3 copies) 
(Supplementary Figure 9). We tested three different sgRNAs targeting the BFP protein 
chromophore region and using flow cytometry, assayed the loss of fluorescence as a direct 
indicator of insertion and deletions (INDELS) caused by CRISPR-Cas9 DSBs 
(representing the NHEJ pathway). The small guide RNA one (sgRNA #1) had the highest 
efficiency and was used for the rest of this study (Figure 9 C, D). 
3.4.3 Effects of ssODN parameters on HDR 
We tested different single-stranded oligodeoxynucleotide (ssODN) repair 
templates with either asymmetric 67-30nt or symmetric 45-45nt homology arms with and 
without 5’ and 3’ phosphorothioate (PS) modifications. In addition, we also evaluated the 
orientation in either a Watson (PAM strand for sgRNA#1) or Crick conformation 
(Supplementary Figure 12). We did not observe significant differences among the 
groups on either the percent of R ratios or HR. It is important to disclose that we tested 
same mass and not same molarity for each of the repair templates (Figure 9 E-G). Based 
on our results and on the work of Liang, et al., (181) we chose an asymmetric ssODN with 
PS modifications in a Watson orientation for the remainder of this study. However, these 
data could not support this choice over any other. 
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Figure 9. Gene Editing Outcomes Quantification by FLow Cytometry. 
A. Comparison between the DNA and amino acid sequences of the enhanced green fluorescent protein 
(eGFP) and the blue fluorescent protein (BFP). We designed a sgRNA (purple) that guides Cas9 to 
introduce a specific double stranded break (DSB). When a single-stranded oligodeoxynucleotide (ssODN) 
repair template is provided, two single base pair changes in the chromophore region of the BFP gene, 
mediate the conversion from blue to green emission. B. Illustration of the experimental design, HEK293 
BFP cells transfected with CRISPR-Cas9 and C16 plasmids that carry the mCherry marker for quantifying 
transfection efficiency. C. The CRISPR-Cas9 induction for insertions and deletions (INDELS) causes a 
loss of BFP fluorescence and can be used as an estimate of the non-homologous end joining pathway 
(NHEJ), sgRNA efficiency was quantify as the percent of BFP negative cells. D. Gene editing outcome 
quantification by flow cytometry, matrix composed of two gates for evaluating GFP and BFP expression. 
HEK293 cells show no fluorescence and locate in the bottom left third, HEK293 BFP cells locate upper 
left third. The CRISPR-Cas9 induction for insertions and deletions (INDELS) causes a loss of BFP 
fluorescence and can be used as an estimate of the non-homologous end joining pathway (NHEJ), when 
providing a ssODN the GFP positive cells locate in the right third. In order to stablish an efficient assay, 
different repair templates were tested, graph E shows HR and NHEJ rates, graph F shows HR rates and 
graph G shows editing ratios (R) calculated as (HDR/(NHEJ+HDR)). One way ANOVA, different letters 
signify statistical differences p < 0.05.  
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Figure 10. Effects of C16 on HDR Rates. 
C16 effects on HDR rates when co-transfected CRISPR-Cas9 using either A-E) Lipofectamine 3000 or F-
J) the Neon electroporation system. Each dot represents one biological replicate mean from two or more 
technical replicates. Values with different subscripts are different (P<0.05). 
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Figure 11. Effect of Increased Concentration of Donor Template and Sequential Delivery 
of C16. 
A-D) C16 effects on HDR rates when co-transfected CRISPR-Cas9 under increasing concentrations of 
repair template (0.5, 1.25µg, 2.5µg and 5.0µg). E-F) C16 effects on HDR rates when transfected sequentially 
48h later with CRISPR-Cas9. 
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3.4.4 Effects of C16 on HDR rate 
In order to evaluate the effect of C16 on homologous recombination (HR) rates, 
we first employed liposomal transfection (Lipofectamine 3000, Thermo) to deliver C16 
with either no NLS or a C-Terminus NLS (Figure 7 G, H), together with the CRISPR-
Cas9 px458 plasmid and the asymmetric repair template (Watson-PS-ssODN) into our 
HEK293 BFP reporter cell line (Figure 10 A-E). Transfection efficiency was highly 
variable due to the poor adherence of our cells, that only mildly improved in either Type-
I collagen or gelatin coated plates. However, the presence of the C-terminal 3xNLS C16 
or C16 without NLS, increased the number of green cells, improving baseline HR 
(CRISPR-Cas9 and ssODN, without C16) from 5.73% (0.4% - 14.36%) to 10.09% (0.8% 
- 25.00%) and 10.47% (0.87% -27.18%) (Figure 10 A) representing a 1.80 and 1.53-fold 
improvement on normalized HR rates (Figure 10 E) respectively (n=3, P<0.05). 
Although, no significant differences were observed on R ratios (HR/NHEJ+HR) and 
normalized R ratios, there was a tendency (p=0.0541) for the C-terminus NLS C16 to 
improve the normalized R ratios.  
 
We next evaluated C16 HR improvements using electroporation with the Neon 
Transfection System (Thermo®). Although initial baseline HDR improved with 
electroporation to 16.7% ± 7.2 compared to lipofectamine (5.7±7.5) (P=0.0521) 
(Supplementary Figure 13), no significant differences were found between the different 
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treatment groups on either R ratios, relative R ratios or relative HR (n= 3-6) (Figure 10 
F-J). We hypothesized that this could be due because there was not enough repair template 
available to allow for HR rates to increase or because of the higher transfection efficiency 
was leading to different molecular stoichiometries between the different vectors that might 
be influencing gene-editing efficiencies, which may limit the amount of C16 protein 
available before the CRISPR-Cas9 DSB was introduced.  
 
In order to test this hypothesis, we optimized our electroporation conditions 
(Supplementary Figure 10) and tested increasing concentrations of ssODN (0.5, 1.25µg, 
2.5µg and 5.0µg) comparing the baseline HR (No C16) with a C-terminus NLS C16 or 
C16 without NLS. It is important to disclose that the baseline HR group in each of the 
treatments was not compensated for the extra 750ng of DNA from the C16 plasmid, so 
the total amount of DNA transfected in the control is lower (e.g 1.25µg total DNA in the 
0.5µg of ssODN group) than in the C-NLS C16 and No NLS C16 groups (e.g 2µg total 
DNA in the 0.5µg of ssODN group). Significant differences were found in the HR% of 
the 1.25µg ssODN no C16 (28.54%) versus the 0.5µg ssODN C-NLS c16 (9.76%) and the 
5.0µg ssODN C-NLS c16 (10.68%) (n=2, p<0.05) (Figure 11 A). Editing ratio (R) and 
HR rates peaked at an average of 40.59% and of 28.54 % for 1.25µg of ssODN. No 
significant differences were found in the HR rates or relative HR ratios normalized to the 
0.5µg no C16 group (22.41 % HR) or (Figure 11 A-D).  
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To address our second hypothesis, we the tested the sequential delivery of C16 
followed 48h later by the CRISPR-Cas9 plasmid and the ssODN repair template.  During 
this experiment, we also evaluated under our conditions the effect of the RAD-51 
stimulatory compound RS-1 (15µM) and the DNA-Ligase IV inhibitory compound SCR7 
(80µM). No significant differences were found in either NHEJ, HR, R or relative R rates 
(n=3) (Figure 11 E-H)  
3.5 Discussion 
To test our initial hypothesis, we established of the BFP to GFP conversion assay first 
reported by Glasser et al., (254), which has been used by many other laboratories to study 
the improvement of genome editing outcomes and the biochemical optimization of the 
CRISPR-Cas9 system(146, 164, 255, 256). In our hands, we were able to obtain on 
average ~ 20% total HR (up to 30% HR, Supplementary Figure 11) rates representing ~ 
40% of the total editing events (R), while using a plasmid based CRISPR-Cas9 system 
and an ssDNA donor template. We created a heterogeneous population of BFP cells with 
different single transgene integration sites at different locus in order to avoid locus bias in 
our HDR experiments. Although we maintained the cells under constant puromycin 
selection (2µg/ml) for 15days before beginning our experiments, we noticed that not 
continuing this selection after transfections lead to silencing of the transgene, as seen by 
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an increase of BFP negative cells in our control populations 72h after transfection cells 
were maintained under puromycin selection.  
 
In this study, we did not find any significant differences in the gene editing outcomes 
between the different parameters being tested with respect to the ssODN repair template 
(Figure 9 E-G). The evaluated criteria were the symmetry and of the homology arms, the 
presence of PS modifications and the strand orientation. Although this is likely due to the 
large variability of the experiment, it is also worth noting that in this study comparisons 
were done with mass instead of molarity between the different repair templates. Other 
groups have reported that an asymmetric ssODN with PS modifications had up to 56% 
HR in HEK293 cells (181). Similarly, the Corn group reported that after investigating the 
interaction of Cas9 with target DNA and discovering that Cas9 releases the PAM-distal 
non-target strand after cleavage but before dissociation they used this finding to rationally 
design a ssDNA that matches this strand, they increased HR rates with up to 60% HR in 
the absence of any chemical intervention(164) (Figure 1 B).  
 
We then examined the re-localization of C16 from the cytoplasmic to the nuclear 
compartment. As the VACV replication cycle occurs in the cytoplasm, C16 is a 
cytoplasmic protein (249). This was achieved by adding a nuclear localization signal 
(3xNLS) at either the N, C terminus or both. The lower fluoresce intensity of the constructs 
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carrying a N terminus NLS, suggests that the presence of the NLS might affect the folding 
or the protein production dynamics of the protein (Figure 8). 
 
A 3xNLS C terminus tagged C16 was able to increase low baseline HR rates of an 
average of 5.73% to 10.09%, representing a moderate ~80% increase in the BFP to GFP 
conversion assay in HEK293. These experiments were performed using a liposomal based 
transfection system (Lipofectamine 3000) that produced large variability due to the 
inability of our cells to remain attached to the plates. These results have similar 
improvement rates to the work of of Gutschner et al.,(158) where a 1.87-fold increase was 
obtained when fusing Cas9 to the N-terminal region of human Geminin, although with 
very low overall rates of a maximum 0.59% HR. This same strategy was later taken and 
improved by another group where they recently indicated that a Cas9- GFP-geminin 
enhanced the HDR/NHEJ ratio 2.7 fold in U2-OS and 1.8 fold K562 cells and is now 
commercially available (182).  
 
We decided to further characterize for how this protein would behave at the higher 
range of HDR rates. For this we decided to change methodology and use the Neon 
electroporation system (Thermo®) that would allow for higher and more consistent 
transfection rates. Although baseline HDR improved to 13.56 % ± 8.25 (Supplementary 
Figure 13), no significant differences were found between the different treatment groups 
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(Figure 10 F-J). We hypothesized that this could be either due because there was not 
enough repair template available to allow for HR rates to increase or because of the higher 
transfection efficiency was leading to different molecular stoichiometries between the 
different vectors that might be influencing gene-editing efficiencies by causing for not 
enough C16 protein to be present before the CRISPR-Cas9 DSB was introduced. This 
hypothesis was tested by evaluating the effect of a gradual increase in the amount of repair 
template and by evaluating the transfection of the C16 plasmid followed 48h later of the 
CRISPR-Cas9 plasmid and ssODN. However, no significant differences were found 
(Figure 11). During this second experiment, we also evaluated under our conditions the 
effect of RS-1 (15µM) and SCR7 (80µM) but did not observe any significant differences 
in HDR (Figure 11 E-H). It is important to note that we used a lower dose of SCR7 due 
to reagent availability in our laboratory and the time frame to perform these experiments. 
Although the original publication by Chu et al., demonstrated that SCR7 increased HDR 
(up to 19-fold at a concentration of 1 µM ) (167), other reports indicate a very high 
variability of this molecule between different experimental systems (158); or even that 
SCR7 is neither a selective nor a potent inhibitor of the human DNA ligase IV (178).  
 
RS-1 is a Rad51 stimulatory molecule identified by a small molecule screen where 
it was shown to stabilize association of RAD51 with DNA(179). Rad51 is a key molecule 
in the HDR pathway that displaces RPA to form a RAD51–ssDNA nucleofilament 
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recombinase, which is required for homology search, strand invasion and ultimately the 
repair of the DSB lesion (148) (Figure 1). Song et al.,(172) reported RS-1 improves HR 
rates 2-5 fold at a concentration of 7.5µM in vitro and in vivo (from 4.4 to 26.1%). RS-1 
was also shown to improve HR rates in HEK cells (from 3.5 to 21%) at and U2OS cells 
(from 1.9 to 2.4%) at a concentration of 10µM, but this varied depending on the locus and 
transfection method, with electroporation (~3-fold) having lower efficiency than with 
lipofectamine (~6-fold) (180). It is important to note that the HR repair with a ssODN has 
been recently referred to as single stranded template repair (SSTR) (117, 237) and it has 
been identified as a RAD51/BRCA2 independent pathway (154) so the type of donor 
being used is one of the possible explanations of the variability of the results obtained with 
RS-1. Zhang et al.,(257) reported that RS-1 did not improved HR rates in hiPSCs at the 
same concentration of 10µM. Interestingly, they also report that the overexpression of 
RAD51 or of the adenovirus 4 (Ad4) proteins 4E1B-E4orf6, which mediate the 
ubiquitination and proteosomal degradation of DNA ligase IV; were detrimental to their 
HR rates. One explanation they give is that after optimization of their donor vector, they 
obtained high-level of HR and these high rates masked the subtle changes mediated by 
many of this inhibitors and proteins. The co-expression of these same adenovirus proteins 
together with the CRISPR-Cas9 system using a 2A peptide was reported by Chu et al., 
(167) to improve HDR efficiency up to ~8-fold reaching HR frequencies of 50-66% and 
significantly decreased NHEJ activity in HEK293 and mouse Burkitt lymphoma-like cell 
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lines. This same work reports the use of shRNA sequences to knock down KU70, KU80 
or DNA ligase IV, which resulted in substantial suppression of the NHEJ and a ~5-fold 
improvement in HR.  
 
Following the same small molecule inhibition strategy, Robert el, al (170) reported 
the inhibition of the DNA-PKcs using the small molecules NU7441 and KU-0060648, 
which caused a decrease of ~40 % in NHEJ events with a ~2-fold increase in HDR, 
although HDR rates were low ~4 % HR; they also show the additive effect of combining 
these two compounds with either RS-1, SCR7, siRNA suppression of Ku70 and Ku80 and 
adenovirus proteins E1B55K and E4orf6, these last being the most efficient inhibiting 
NHEJ ~8-fold and stimulating HR ~3.5 fold, in line Chu, et al., (167) . 
 
In our study, we observed a transfection methodology variability effect similar to 
the one described by Song et al.,(172), We also found no effect of the C16 protein after 
optimizing for higher HDR rates just as described Zhang et al.,(257). Zhang et, observed 
that the use of the Ad4 proteins 4E1B-E4orf6d were even detrimental to their HR rates, 
but Chu et al., (167) obtained ~8-fold HR improvement when co-expressed with the 
CRISPR-Cas9 system using a 2A sequence. This would lead us to believe that expressing 
C16 in a bi-cistronic construct with CRISPR-Cas9 would lead to a better performance of 
the system. Further, in this study, we used an optimized asymmetric sODN that is using 
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the SSTR pathway and if we considered that HDR is required for repairing lesions using 
double-stranded, but not single-stranded DNA as a template(154), in order to evaluate the 
effects of C16 on the HDR pathway, we would need to evaluate using a dsDNA donor 
with homology arms longer than 100bp (137). 
 
Smith et al., demonstrated that C16 could inhibit the DNA-mediated activation of the 
innate immune system, resulting in approximately a 50% reduction in the production of 
the pro-inflammatory molecules Cxcl10 and Il-6 (245). This was in line with a report 
where MEFs lacking the Ku heterodimer induce lower levels of cytokines and chemokines 
induced upon stimulation with DNA (244). This residual signaling, was explained by the 
Smith group as by DNA-PKcs having DNA-binding capability independent of Ku (258), 
although this interaction is greatly enhanced by the presence of the Ku heterodimer, and 
by the existence of other DNA sensing mechanism (249, 259, 260) such as IFI16 (261) 
and cGAS (262). Another reason is that C16 does not bind Ku70/80 in direct competition 
with DNA-PKcs, although it reduces the amount of DNA-PKcs bound to DNA (245, 249). 
Additionally, there is a multi-functional role of C16, as this protein was also show to 
reprogram cellular energy metabolism towards increased synthesis of the metabolic 
precursors utilized during viral replication, via the stabilization of the hypoxia-inducible 
transcription factor (HIF)-1 alfa. Finally an incomplete penetrance of the cells with the 
C16-encoding plasmid and the high abundance of the Ku molecules in cells (KU70 
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1,290,000 and KU80 826,000 molecules per cell) (137) can make the inhibition of these 
molecules under our conditions challenging. 
 
3.6 Conclusions 
In summary, our study introduces a new approach to the efforts of the manipulation of 
the gene editing outcomes, by the adaptation of the naturally evolved VACV-C16 protein 
to target the Ku heterodimer in the mammalian nucleus. We recognize that the observed 
enhancement in our study is moderate and that under the conditions tested is only 
beneficial at low basal HR rates. We show the need for a refinement of the spatiotemporal 
expression of this protein. More research will be needed in order to reveal the full potential 
of this genome engineering tool in the future.  
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CHAPTER IV  
SUMMARY AND CONCLUSIONS 
 
In this work, we have shown that genome editing technologies can be used for the 
therapeutic genome editing of genetic diseases in animals by successfully correcting the 
GBED mutation with moderate efficiency (~20%) in a heterozygous cell line derived from 
a high genetic merit American Quarter Horse stallion using CRISPR-Cas9 that will be 
used to generate a cloned animal.  In order to make the correction of genetic diseases it is 
necessary to increase the efficiency of precise genome editing, this was the main objective 
for the second part of our work where we created a new approach to the efforts of the 
manipulation of the gene editing outcomes, by the adaptation of the naturally evolved 
VACV-C16 protein to target the Ku heterodimer in the mammalian nucleus. We recognize 
that the observed enhancement in our study is moderate and that under the conditions 
tested is only beneficial at low basal HR rates. We show the need for a refinement of the 
spatiotemporal expression of this protein. More research will be needed in order to reveal 
the full potential of this genome engineering tool in the future.  
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Supplementary Figure 1. Equine Chromosome Ideogram of CIRSPR-Cas9 On Target and 
Predicted Off Target Sites for the sgRNA +1. 
Equine chromosome ideogram, illustrating only one chromosome of each of the 32 pairs with the exception 
of the X and Y chromosomes. Each predicted off-target chromosome and approximate location within the 
chromosome is shown (red arrow head). On-Target location in chromosome 26 is shown (green arrow head).  
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Supplementary Figure 2. CRISPR-Cas Induced DSB at the GBE1 Locus Have 
Unidirectional Repair Tracts and Non-Random INDEL Outcomes. 
Fasta sequences of the aligned chromatographs (Benchling®) of a subset of colonies of sgRNA +15. Note 
that the majority of the INDEL events are located 3’ of the sgRNA location, this represent the unidirectional 
repair tracts. A closer examination shows that several of this INDELS are non-random with approximately 
45% of the events being repetitive, some events are more prevalent with 24% of the sequence reads being 
identical (Red square).  
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Supplementary Figure 3. CRISPResso Analysis of Genome Editing Outcomes on sgRNA 
+1. 
A) Quantification of editing frequency as determined by the percentage and number of sequence reads 
showing unmodified and modified alleles. Modified alleles are subdivided into C-NHEJ, HDR and mixed 
HDR-C-NHEJ alleles. Frequency distribution of B) size and C) frequency of alleles with indels (shown in 
blue) and without indels (in red). D), E) C-NHEJ reads, F) mixed HDR-C-NHEJ reads and G) HDR reads 
with insertions (red), deletions (purpule) and substitutions (green) mapped to reference amplicon position. 
The predicted Cas9 clevage site is indicated by a vertical dash line. Only sequence positions directly adjacent 
to insertions or directly affected by deletions or substitutions are plotted. H) Left panel, frequency 
distribution of sequence modifications that increase read length with respect to the reference amplicon, 
classified as insertions (positive indel size). Middle panel, frequency distribution of sequence modifications 
that reduce read length with respect to the reference amplicon, classified as deletions (negative indel size). 
Right panel, frequency distribution of sequence modifications that do not alter read length with respect to 
the reference amplicon, which are classified as substitutions (number of substituted positions shown). I) 
Position dependent insertion size (left) and deletion size (right). 
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Supplementary Figure 4. FISH Stain of Isolated BAC Clones.  
Fluorescent in-situ Hybridization of BACs 93G22 and 112C9 containing the GBE1 sequence of interest, 
that were detected conjointly with the control probes ETSTY7 bio + ETSTY dig targeting the Y 
chromosome. 
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Supplementary Figure 5. Expected Digestion Fragments of C16 Vector. 
This is an illustration of the ideal expected sizes of the C16 enzyme restriction fragments with the following 
enzymes: 1) Bgl Il; 2) Kpn I; 3) Bgl II and Kpn I; 4) Bgl II and Eco RI; 5) Eco RI. 
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Supplementary Figure 6. Digestion Fragments of C16 Vector. 
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Supplementary Figure 7. Sequencing Alignment of C16 Vector Variants. 
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Supplementary Figure 8. FACS for the Establishment of a BFP-HEK293 Cell Line. 
Fluorescent activated flow cytometry (FACS) of A) HEK293 cells transduced with lentivirus carrying 
puromycin and blue fluorescent protein (BFP) genes, and B) Second sort for homogeneous expression of 
BFP Transgene. 
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Supplementary Figure 9. ddPCR BFP Copy Number Quantification. 
Copy numbers were calculated based on droplet numbers of the target, (BFP) compared to the single copy 
reference (RPP30) (e.g. BFP/RPP30:∼ 1 = Mono-allelic, ∼ 2.0 = Bi-allelic, ∼ 3.0 = Tri-allelic). Data 
represents two HEK 293 negative controls and four technical replicate samples of genomic DNA extracted 
from FACS sorted GFP+ cells together with a no template control (NTC) as a negative control. 
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Supplementary Figure 10. Neon Transfection System Optimization. 
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Supplementary Figure 11. Maximum HR Rates Obtained Under Our Conditions. 
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Supplementary Figure 12. Designed Repair Templates.  
Illustration of the different single-stranded oligodeoxynucleotide (ssODN) repair templates with either 
asymmetric 67-30nt or symmetric 45-45nt homology arms with and without 5’ and 3’ phosphorothioate (PS) 
modifications. In in either a Watson (PAM strand for sgRNA#1) or Crick conformation. 
 
 
 
 
Supplementary Figure 13. HDR Rates Comparison Between Lipofectamine and 
Electroporation. 
 
  
 
145 
 
 
Supplementary Figure 14. DNA Double Strand Breaks. 
Gene editing technologies, including CRISPR-Cas9, rely on the precise introduction of a DNA double-
strand breaks (DSBs) are the most dangerous type of DNA damage, which if left unrepaired, can result in 
chromosomal translocations, the loss of large chromosomal regions or can activate cell cycle check-point 
arrests and induce signals for programmed cell death. In dividing mammalian cells, there are an estimated 
ten DNA double-strand breaks (DSBs) per day per cell (137). These pathological DSBs arise from DNA 
replication errors, reactive oxygen species, and genotoxic agents such as ionizing radiation, radiomimetic 
chemicals or topoisomerase inhibitors (138). There are also physiological DSBs that arise during normal 
cellular processes, such as meiosis during gametogenesis or V(D)J recombination and class-switch 
recombination (CSR) which facilitate the rearrangements of antigen receptor genes in lymphogenesis (137, 
138). DSBs that occur throughout the cell cycle are repaired predominantly by the non-homologous DNA 
end joining (NHEJ) pathway that is present during the G1, S and G2 phases and to a lesser extent by the 
homology-directed repair (HDR) pathway that is restricted during the late S and G2 phases(139). 
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Supplementary Table 1. Sequencing Primers Used. 
 
Name Sequence 
C16 Seq FW # 1 CTT CTC CTC CGG GCT GTA AT T AG 
C16 Seq FW # 2 GAT AAA ACT TTA CCA CCC TA C TG 
C16 Seq FW # 3 CAC CGA ACC TCC GAC AGT CT 
C16 Seq RV # 1 CTT GTT TAT TGC AGC TTA TAA TGG TTA C 
 
 
 
 
Supplementary Table 2. Sequence of sgRNA Targeting the BFP Chromophore. 
 
Name Sequence PAM Strand 
sgRNA BFP # 1 CTCGTGACCACCCTGAGCCA CGG + 
sgRNA BFP # 2 GGCTGAAGCACTGGACGCCG TGG - 
sgRNA BFP # 3 AGCACTGGACGCCGTGGCTC AGG - 
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APPENDIX C 
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Supplementary Material 1. GBED ssODN Repair Templates Used. 
 
GBED Symmetric repair template  
GCTCCGACGCGGCGCTGGCGGCGGCCCTGGCGGACGTGCCCGACCTGGGCC
GCCTTCTGGAGGTCGACCCGTACCTGAAGCCCTACGCCCCGGACTTCCAGCG
CA 
GBED Symmetric repair template with PAM silence mutation 
GCTCCGACGCGGCGCTGGCGGCGGCCCTGGCGGACGTGCCCGACCTGGGCC
GGCTTCTGGAGGTCGACCCGTACCTGAAGCCCTACGCCCCGGACTTCCAGCG
CA 
GBED PS asymmetric repair template  
A*C*G CGG CGC TGG CGG CGG CCC TGG CGG ACG TGC CCG ACC TGG GCC 
GCC TTC TGG AGG TCG ACC CGT ACC TGA AGC CCT ACG CCC CGG ACT TCC 
AGC* G*C  
 GBED PS asymmetric repair template  
ACG CGG CGC TGG CGG CGG CCC TGG CGG ACG TGC CCG ACC TGG GCC 
GCC TTC TGG AGG TCG ACC CGT ACC TGA AGC CCT ACG CCC CGG ACT TCC 
AGCGC  
Supplementary Material 2. GBE1 5’ UTR Exon 1 CDS. 
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CDS: 135…264, Feature: GBE1 exon1 
CTCGCCGCTATAAAGGGCCCCGGGCCGCAGCCGCTCGCCTCGGCGTCCTCGG
CTCCGCCCTCGCGCCGGCCACTCCGCGGAGCTCGTTCCCGCTCGAGCGGCTC
GGGCCTCGGCTACTCGGGCTGCGGCCGAAGATGGCGGCGCCGGCGGCTCGG
GCCGACGGCTCCGACGCGGCGCTGGCGGCGGCCCTGGCGGACGTGCCCGAC
CTGGGCCGCCTTCTGGAGGTCGACCCGTACCTGAAGCCCTACGCCCCGGACT
TCCAGCGCA 
 
Supplementary Material 3. C16 – mCherry Codon Optimized Construct Sequence.  
 
CDS: 1…81, Feature: 3xNLS. CDS:  82...87, Feature: BglII. CDS:  88…1080, Feature: 
C16. CDS: 1081…1086, Feature: EcoRI. CDS: 1087…1116, Feature: (Gly 4 Ser 4)2 GS 
linker. CDS: 1117…1824, Feature: mCherry. CDS: 1825…1830, Feature: EcoRI. CDS: 
1831…1836, Feature: KpnI. CDS: 1837…1911, Feature: 3xNLS. CDS: 1912…1917, 
Feature: KpnI. CDS: 1918…1920, Feature: Stop. 
ATGAGATCTGATCCAAAAAAGAAGAGAAAGGTAGATCCAAAAAAGAAGAG
AAAGGTAGATCCAAAAAAGAAGAGAAAGGTAAGATCTATGGACATATATGA
TGATAAGGGCCTTCAGACGATTAAGCTGTTCAATAACGAATTTGATTGCATA
AGGAACGACATAAGAGAACTCTTTAAGCATGTAACTGACAGTGACTCAATTC
AACTGCCAATGGAGGACAACTCCGACATCATTGAAAATATACGAAAGATAC
TTTACAGACGACTTAAGAATGTGGAGTGCGTTGACATTGACTCAACAATTAC
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CTTTATGAAGTACGATCCGAACGATGATAATAAGCGCACGTGTTCAAATTGG
GTTCCACTTACTAATAATTACATGGAATATTGCCTCGTGATATACCTCGAAA
CACCCATCTGTGGGGGCAAGATAAAACTTTACCACCCTACTGGGAATATCAA
ATCAGATAAGGATATCATGTTTGCGAAAACATTGGACTTCAAATCCAAGAAA
GTCTTGACAGGCCGGAAGACTATCGCGGTGCTTGATATTTCCGTTAGCTATA
ATCGATCCATGACGACGATCCATTACAACGACGACGTTGACATCGACATACA
CACAGATAAAAACGGAAAAGAACTCTGCTATTGCTATATCACGATCGACGA
TCACTATCTGGTCGATGTCGAAACAATCGGAGTAATCGTTAATCGGTCCGGC
AAGTGTCTGCTCGTTAATAATCATCTTGGCATCGGGATAGTCAAGGACAAAC
GCATCAGTGATTCATTCGGCGATGTGTGCATGGACACTATATTTGACTTCTCT
GAAGCTCGGGAACTCTTCAGTCTTACAAACGATGACAATCGCAATATCGCCT
GGGATACCGATAAGCTTGACGATGACACCGACATCTGGACACCTGTAACGG
AGGATGACTATAAATTTCTTAGTCGATTGGTGTTGTATGCCAAGTCTCAATC
AGATACGGTATTCGATTACTACGTCCTGACTGGGGACACCGAACCTCCGACA
GTCTTCATTTTCAAAGTCACGCGCTTCTACTTTAACATGCCGAAAGAATTCGG
TGGTGGTGGTTCTGGTGGTGGTGGTTCTATGGTGAGCAAGGGCGAGGAGGAT
AACATGGCCATCATCAAGGAGTTCATGCGCTTCAAGGTGCACATGGAGGGCT
CCGTGAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCT
ACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACCAAGGGTGGCCCCCTGC
CCTTCGCCTGGGACATCCTGTCCCCTCAGTTCATGTACGGCTCCAAGGCCTAC
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GTGAAGCACCCCGCCGACATCCCCGACTACTTGAAGCTGTCCTTCCCCGAGG
GCTTCAAGTGGGAGCGCGTGATGAACTTCGAGGACGGCGGCGTGGTGACCG
TGACCCAGGACTCCTCCCTGCAGGACGGCGAGTTCATCTACAAGGTGAAGCT
GCGCGGCACCAACTTCCCCTCCGACGGCCCCGTAATGCAGAAGAAGACCAT
GGGCTGGGAGGCCTCCTCCGAGCGGATGTACCCCGAGGACGGCGCCCTGAA
GGGCGAGATCAAGCAGAGGCTGAAGCTGAAGGACGGCGGCCACTACGACGC
TGAGGTCAAGACCACCTACAAGGCCAAGAAGCCCGTGCAGCTGCCCGGCGC
CTACAACGTCAACATCAAGTTGGACATCACCTCCCACAACGAGGACTACACC
ATCGTGGAACAGTACGAACGCGCCGAGGGCCGCCACTCCACCGGCGGCATG
GACGAGCTGTACAAGGAATTCGGTACCATGGATCCAAAAAAGAAGAGAAAG
GTAGATCCAAAAAAGAAGAGAAAGGTAGATCCAAAAAAGAAGAGAAAGGT
AGGTACCTAG. 
Supplementary Material 4. BFP to GFP Repair templates. 
 
GFP_WATSON_67-30:  
CCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCT
CGTGACCACCCTGACCTACGGCGTCCAGTGCTTCAGCCGCTACCC 
GFP_CRICK_67-30 
GGCGGACTTGAAGAAGTCGTGCTGCTTCATGTGGTCGGGGTAGCGGCTGAA
GCACTGGACGCCGTAGGTCAGGGTGGTCACGAGGGTGGGCCAGGGC 
GFP_PS_WATSON_67-30 
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C*C*CTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCC
TCGTGACCACCCTGACCTACGGCGTCCAGTGCTTCAGCCGCTAC*C*C 
GFP_PS_CRICK_67-30 
G*G*CGGACTTGAAGAAGTCGTGCTGCTTCATGTGGTCGGGGTAGCGGCTGA
AGCACTGGACGCCGTAGGTCAGGGTGGTCACGAGGGTGGGCCAGG*G*C 
GFP_WATSON_90 
CGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGC
GTCCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCA 
GFP_CRICK_90 
TGCTTCATGTGGTCGGGGTAGCGGCTGAAGCACTGGACGCCGTAGGTCAGG
GTGGTCACGAGGGTGGGCCAGGGCACGGGCAGCTTGCCG 
GFP_PS_WATSON_90 
C*G*GCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACG
GCGTCCAGTGCTTCAGCCGCTACCCCGACCACATGAAG*C*A 
GFP_PS_CRICK_90 
T*G*CTTCATGTGGTCGGGGTAGCGGCTGAAGCACTGGACGCCGTAGGTCAG
GGTGGTCACGAGGGTGGGCCAGGGCACGGGCAGCTTGC*C*G 
 
